<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T01:29:52Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:9691552" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:9691552</identifier>
        <datestamp>2023-01-10</datestamp>
        <setSpec>blackwellopen</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" id="sim9591" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">Stat Med</journal-id>
              <journal-id journal-id-type="iso-abbrev">Stat Med</journal-id>
              <journal-id journal-id-type="doi">10.1002/(ISSN)1097-0258</journal-id>
              <journal-id journal-id-type="publisher-id">SIM</journal-id>
              <journal-title-group>
                <journal-title>Statistics in Medicine</journal-title>
              </journal-title-group>
              <issn pub-type="ppub">0277-6715</issn>
              <issn pub-type="epub">1097-0258</issn>
              <publisher>
                <publisher-name>John Wiley &amp; Sons, Inc.</publisher-name>
                <publisher-loc>Hoboken, USA</publisher-loc>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC9691552</article-id>
              <article-id pub-id-type="pmcid">PMC9691552</article-id>
              <article-id pub-id-type="pmc-uid">9691552</article-id>
              <article-id pub-id-type="pmid">36259523</article-id>
              <article-id pub-id-type="pmid">36259523</article-id>
              <article-id pub-id-type="doi">10.1002/sim.9591</article-id>
              <article-id pub-id-type="publisher-id">SIM9591</article-id>
              <article-categories>
                <subj-group subj-group-type="overline">
                  <subject>Research Article</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Research Articles</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Surv‐CRM‐12: A Bayesian phase I/II survival CRM for right‐censored toxicity endpoints with competing disease progression</article-title>
                <alt-title alt-title-type="left-running-head">ANDRILLON et al.</alt-title>
                <alt-title alt-title-type="right-running-head">Surv‐CRM‐12: A Bayesian phase I/II survival CRM for right‐censored toxicity endpoints with competing disease progression</alt-title>
              </title-group>
              <contrib-group>
                <contrib id="sim9591-cr-0001" contrib-type="author" corresp="yes">
                  <name>
                    <surname>Andrillon</surname>
                    <given-names>Anaïs</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-4804-4611</contrib-id>
                  <xref rid="sim9591-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="sim9591-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                  <address>
                    <email>anais.andrillon@u-paris.fr</email>
                  </address>
                </contrib>
                <contrib id="sim9591-cr-0002" contrib-type="author">
                  <name>
                    <surname>Chevret</surname>
                    <given-names>Sylvie</given-names>
                  </name>
                  <xref rid="sim9591-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib id="sim9591-cr-0003" contrib-type="author">
                  <name>
                    <surname>Lee</surname>
                    <given-names>Shing M.</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0001-8413-6869</contrib-id>
                  <xref rid="sim9591-aff-0002" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib id="sim9591-cr-0004" contrib-type="author">
                  <name>
                    <surname>Biard</surname>
                    <given-names>Lucie</given-names>
                  </name>
                  <contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0660-1264</contrib-id>
                  <xref rid="sim9591-aff-0001" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
              </contrib-group>
              <aff id="sim9591-aff-0001">
                <label>
                  <sup>1</sup>
                </label>
                <named-content content-type="organisation-division">ECSTRRA Team, UMR‐1153</named-content>
                <institution>Université de Paris, INSERM, AP‐HP, Hôpital Saint Louis</institution>
                <city>Paris</city>
                <country country="FR">France</country>
              </aff>
              <aff id="sim9591-aff-0002">
                <label>
                  <sup>2</sup>
                </label>
                <named-content content-type="organisation-division">Department of Biostatistics</named-content>
                <institution>Mailman School of Public Health, Columbia University</institution>
                <city>New York</city>
                <named-content content-type="country-part">New York</named-content>
                <country country="US">USA</country>
              </aff>
              <author-notes>
                <corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold> Anaïs Andrillon, Hôpital Saint Louis, Service de Biostatistique et Information Médicale, 1 Avenue Claude Vellefaux, 75010 Paris, France.<break/>
Email: <email>anais.andrillon@u-paris.fr</email>
<break/>
</corresp>
              </author-notes>
              <pub-date pub-type="epub">
                <day>19</day>
                <month>10</month>
                <year>2022</year>
              </pub-date>
              <pub-date pub-type="ppub">
                <day>20</day>
                <month>12</month>
                <year>2022</year>
              </pub-date>
              <volume>41</volume>
              <issue seq="110">29</issue>
              <issue-id pub-id-type="doi">10.1002/sim.v41.29</issue-id>
              <fpage>5753</fpage>
              <lpage>5766</lpage>
              <history>
                <date date-type="rev-recd">
                  <day>15</day>
                  <month>9</month>
                  <year>2022</year>
                </date>
                <date date-type="received">
                  <day>16</day>
                  <month>12</month>
                  <year>2021</year>
                </date>
                <date date-type="accepted">
                  <day>23</day>
                  <month>9</month>
                  <year>2022</year>
                </date>
              </history>
              <permissions>
                <!--&#x000a9; 2022 John Wiley & Sons, Ltd.-->
                <copyright-statement content-type="article-copyright">© 2022 The Authors. <italic toggle="yes">Statistics in Medicine</italic> published by John Wiley &amp; Sons Ltd.</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbyncndlicense">https://creativecommons.org/licenses/by-nc-nd/4.0/</ali:license_ref>
                  <license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">http://creativecommons.org/licenses/by-nc-nd/4.0/</ext-link> License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf" xlink:href="file:SIM-41-5753.pdf"/>
              <abstract id="sim9591-abs-0001">
                <p>The growing interest in new classes of anti‐cancer agents, such as molecularly‐targeted therapies and immunotherapies with modes of action different from those of cytotoxic chemotherapies, has changed the dose‐finding paradigm. In this setting, the observation of late‐onset toxicity endpoints may be precluded by treatment and trial discontinuation due to disease progression, defining a competing event to toxicity. Trial designs where dose‐finding is modeled in the framework of a survival competing risks model appear particularly well‐suited. We aim to provide a phase I/II dose‐finding design that allows dose‐limiting toxicity (DLT) outcomes to be delayed or unobserved due to competing progression within the possibly long observation window. The proposed design named the Survival‐continual reassessment method‐12, uses survival models for right‐censored DLT and progression endpoints. In this competing risks framework, cause‐specific hazards for DLT and progression‐free of DLT were considered, with model parameters estimated using Bayesian inference. It aims to identify the optimal dose (OD), by minimizing the cumulative incidence of disease progression, given an acceptable toxicity threshold. In a simulation study, design operating characteristics were evaluated and compared to the TITE‐BOIN‐ET design and a nonparametric benchmark approach. The performance of the proposed method was consistent with the complexity of scenarios as assessed by the nonparametric benchmark. We found that the proposed design presents satisfying operating characteristics in selecting the OD and safety.</p>
              </abstract>
              <kwd-group kwd-group-type="author-generated">
                <kwd id="sim9591-kwd-0001">competing risks</kwd>
                <kwd id="sim9591-kwd-0002">dose‐finding</kwd>
                <kwd id="sim9591-kwd-0003">oncology</kwd>
                <kwd id="sim9591-kwd-0004">phase I/II</kwd>
                <kwd id="sim9591-kwd-0005">survival data</kwd>
              </kwd-group>
              <funding-group>
                <award-group id="funding-0001">
                  <funding-source>
                    <institution-wrap>
                      <institution>National Center for Advancing Translational Sciences
</institution>
                      <institution-id institution-id-type="doi">10.13039/100006108</institution-id>
                    </institution-wrap>
                  </funding-source>
                  <award-id>UL1TR001873</award-id>
                </award-group>
              </funding-group>
              <counts>
                <fig-count count="1"/>
                <table-count count="1"/>
                <page-count count="14"/>
                <word-count count="6956"/>
              </counts>
              <custom-meta-group>
                <custom-meta>
                  <meta-name>source-schema-version-number</meta-name>
                  <meta-value>2.0</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>cover-date</meta-name>
                  <meta-value>20 December 2022</meta-value>
                </custom-meta>
                <custom-meta>
                  <meta-name>details-of-publishers-convertor</meta-name>
                  <meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:6.2.3 mode:remove_FC converted:09.01.2023</meta-value>
                </custom-meta>
              </custom-meta-group>
            </article-meta>
            <notes>
              <p content-type="self-citation">
                <mixed-citation publication-type="journal" id="sim9591-cit-1001"><string-name><surname>Andrillon</surname><given-names>A</given-names></string-name>, <string-name><surname>Chevret</surname><given-names>S</given-names></string-name>, <string-name><surname>Lee</surname><given-names>SM</given-names></string-name>, <string-name><surname>Biard</surname><given-names>L</given-names></string-name>. <article-title>Surv‐CRM‐12: A Bayesian phase I/II survival CRM for right‐censored toxicity endpoints with competing disease progression</article-title>. <source>Statistics in Medicine</source>. <year>2022</year>;<volume>41</volume>(<issue>29</issue>):<fpage>5753</fpage>‐<lpage>5766</lpage>. doi:<pub-id pub-id-type="doi">10.1002/sim.9591</pub-id>
<pub-id pub-id-type="pmid">36259523</pub-id></mixed-citation>
              </p>
              <fn-group>
                <fn id="sim9591-note-1002">
                  <p><bold>Funding information</bold> National Center for Advancing Translational Sciences, UL1TR001873</p>
                </fn>
              </fn-group>
            </notes>
          </front>
          <body id="sim9591-body-0001">
            <def-list list-content="abbreviations" id="sim9591-dl-0001">
              <title>Abbreviations</title>
              <def-item>
                <term>CRM</term>
                <def>
                  <p>continual reassessment method</p>
                </def>
              </def-item>
              <def-item>
                <term>DLT</term>
                <def>
                  <p>dose limiting toxicity</p>
                </def>
              </def-item>
              <def-item>
                <term>MTD</term>
                <def>
                  <p>maximum tolerated dose</p>
                </def>
              </def-item>
              <def-item>
                <term>MTA</term>
                <def>
                  <p>molecularly‐targeted therapies</p>
                </def>
              </def-item>
              <def-item>
                <term>PCS</term>
                <def>
                  <p>probability of correct selection</p>
                </def>
              </def-item>
            </def-list>
            <sec id="sim9591-sec-0002">
              <label>1</label>
              <title>INTRODUCTION</title>
              <p>Historically, phase I cancer dose‐finding clinical trial designs were developed for cytotoxic drugs and aimed at defining the maximal tolerated dose (MTD) of a new drug from a small and finite set of fixed dose levels; in this setting, the outcome is commonly measured by the occurrence of dose‐limiting toxicities (DLT) over a short period of time. This paradigm has been challenged with the arrival of new classes of anticancer agents, such as molecularly‐targeted therapies (MTAs) and immunotherapies. Their modes of action target the immune system or tumor specific pathways and differ from those of cytotoxic chemotherapies. In contrast to cytotoxic chemotherapies, which are administrated at discrete time points and may cause acute severe toxicities, new agents may be responsible for late‐onset toxicities, related to their pharmacological properties or prolonged and continuous administration.<xref rid="sim9591-bib-0001" ref-type="bibr"><sup>1</sup></xref>, <xref rid="sim9591-bib-0002" ref-type="bibr"><sup>2</sup></xref>, <xref rid="sim9591-bib-0003" ref-type="bibr"><sup>3</sup></xref> To handle such prolonged observation windows of toxicities,<xref rid="sim9591-bib-0004" ref-type="bibr"><sup>4</sup></xref> a number of model‐based designs have been proposed. Cheung and Chappell,<xref rid="sim9591-bib-0005" ref-type="bibr"><sup>5</sup></xref> introduced the time‐to‐event continual reassessment method (TITE‐CRM), followed by Braun,<xref rid="sim9591-bib-0006" ref-type="bibr"><sup>6</sup></xref> Yuan and Yin,<xref rid="sim9591-bib-0007" ref-type="bibr"><sup>7</sup></xref> and Liu et al.<xref rid="sim9591-bib-0008" ref-type="bibr"><sup>8</sup></xref> Model‐assisted designs have been also developed to provide solution for phase I trials with late‐onset toxicity. Yuan et al<xref rid="sim9591-bib-0009" ref-type="bibr"><sup>9</sup></xref> proposed the Time‐to‐event Bayesian optimal interval design (TITE‐BOIN) based on the single mean imputation method, while Lin and Yuan<xref rid="sim9591-bib-0010" ref-type="bibr"><sup>10</sup></xref> formulated a general methodology to allow model‐assisted trial designs to accommodate pending DLT data.</p>
              <p>With prolonged observation windows, competing events observed during the trial, such as disease progressions or death, may also occur, resulting in early treatment or study discontinuation. Toxicity assessment may be precluded by such early terminations of the patient exposure to the drug. Usually, the occurrence of a progression followed by the trial discontinuation within the toxicity window results either in patient replacement leading to increased study duration and cost, or implementation of practical strategies to handle those partial observations.<xref rid="sim9591-bib-0011" ref-type="bibr"><sup>11</sup></xref> However, considering progression as an independent censoring event ignores this information related to efficacy, and may impact the operating characteristics of the design, with decreased performances in selecting the correct dose.<xref rid="sim9591-bib-0011" ref-type="bibr"><sup>11</sup></xref> Accounting for any discontinuation event as informative censoring, using the cumulative incidence of DLT in a survival CRM setting improved the design operating characteristics compared to the binomial TITE‐CRM.<xref rid="sim9591-bib-0012" ref-type="bibr"><sup>12</sup></xref> The information provided by efficacy‐related outcomes, such as disease progression, could be also used in the process of selecting a dose, resulting in phase I/II trial designs.<xref rid="sim9591-bib-0013" ref-type="bibr"><sup>13</sup></xref>, <xref rid="sim9591-bib-0014" ref-type="bibr"><sup>14</sup></xref>, <xref rid="sim9591-bib-0015" ref-type="bibr"><sup>15</sup></xref>, <xref rid="sim9591-bib-0016" ref-type="bibr"><sup>16</sup></xref>, <xref rid="sim9591-bib-0017" ref-type="bibr"><sup>17</sup></xref>, <xref rid="sim9591-bib-0018" ref-type="bibr"><sup>18</sup></xref>, <xref rid="sim9591-bib-0019" ref-type="bibr"><sup>19</sup></xref>, <xref rid="sim9591-bib-0020" ref-type="bibr"><sup>20</sup></xref> However, most of these phase I/II designs treat toxicity and efficacy as binary outcomes observed within the timeframe of the trial. Some addressed the issue of late‐onset outcomes in phase I/II, assuming independent toxicity and efficacy outcomes.<xref rid="sim9591-bib-0016" ref-type="bibr"><sup>16</sup></xref>, <xref rid="sim9591-bib-0021" ref-type="bibr"><sup>21</sup></xref>, <xref rid="sim9591-bib-0022" ref-type="bibr"><sup>22</sup></xref> Nevertheless, patients who experience toxicity generally have their dose reduced or discontinued and are inconsistently followed for efficacy or progression. Therefore, the occurrences of progression and DLT compete with each other.</p>
              <p>In this particular setting of phase I/II with delayed outcomes, Takeda et al<xref rid="sim9591-bib-0022" ref-type="bibr"><sup>22</sup></xref> proposed a Time‐to‐event Bayesian optimal interval design (TITE‐BOIN‐ET) to identify the optimal dose (OD), allowing staggered patient accrual by relaxing the need for complete follow‐up of previously included patients. They applied the likelihood approach with pending toxicity data proposed by Lin and Yuan for both efficacy and toxicity outcomes.<xref rid="sim9591-bib-0010" ref-type="bibr"><sup>10</sup></xref> Allowing the continuous enrollment of new patients, when previous patients are still under observation, can shorten the duration of the trial, which is suitable for prolonged observation windows and late‐onset toxicities. However, although the TITE‐BOIN‐ET handles incomplete observations, it relies on binary endpoints for toxicity and efficacy, as stated above. Owing to the competing risks setting, a comprehensive method that formally includes the information of time‐to‐toxicity and time‐to‐progression using a survival working model for right‐censored endpoints, thus allowing the toxicity outcomes to be delayed or unobserved due to competing events within the observation window, appears fully appropriate for new anti‐cancer agents. In this setting, Biard et al recently developed the CR‐CRM, a seamless phase I/II design for novel anti‐cancer agents with competing disease progressions,<xref rid="sim9591-bib-0023" ref-type="bibr"><sup>23</sup></xref> using a survival likelihood framework with three stages: first rule‐based initiation, second toxicity‐centered escalation, and third toxicity and efficacy optimization. The CR‐CRM relies on a cause‐specific approach targeting the marginal latent incidences of events (toxicity and progression) for dose finding, close to a hypothetical situation where the time‐to‐toxicity can be observed in the absence of failure due to progression,<xref rid="sim9591-bib-0024" ref-type="bibr"><sup>24</sup></xref> which may be hard to estimate in practice.</p>
              <p>In this article, we develop a novel Bayesian Survival‐continual reassessment method for phase I/II dose‐finding trials, named the Survival‐CRM‐12 (Surv‐CRM‐12), using survival models for right‐censored and competing DLT and progression endpoints: it allows the outcomes to be delayed or unobserved within the observation window. The proposed method aims to identify the OD, by minimizing the cumulative incidence of disease progression, given an acceptable toxicity threshold. With a single stage design, the Surv‐CRM‐12 design is easier to implement and allows for the use of both toxicity and efficacy information for the entire trial. The Surv‐CRM‐12 also targets the cumulative probability of events within the observation window, taking competing risks into account. It corresponds to an approach based on the observed patient outcomes, accounting for all competing events in dose finding and clinical decision making.</p>
            </sec>
            <sec id="sim9591-sec-0003">
              <label>2</label>
              <title>MOTIVATING EXAMPLE</title>
              <p>The present work was retrospectively motivated by a phase I/II clinical trial setting in patients with low‐risk myelodysplastic syndrome (MDS) to evaluate the tolerance and efficacy of a new targeted therapy combined with erythropoietin (EPO). More specifically, the goal of the trial was to determine the OD level of this targeted therapy in terms of both toxicity and efficacy, with constant dose of EPO. Outcomes were assessed after the first treatment cycle, up to 42 days. The DLT was defined as any grade <mml:math id="jats-math-1" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mo>≥</mml:mo></mml:mrow></mml:mrow></mml:math>3 drug‐related adverse event lasting more than 7 days, or any persisting cytopenias at day 42 without evidence of disease progression in bone marrow and/or peripheral blood. Treatment response was defined at day 21 by an increase in hemoglobin level of 1.5 g/dL or above. Progression free survival (PFS) was a secondary endpoint. The dose‐finding was scheduled to use the TITE‐BOIN‐ET design,<xref rid="sim9591-bib-0022" ref-type="bibr"><sup>22</sup></xref> accounting for possible continuous recruitment during the 42‐days observation window for DLT. However, we wondered whether using a survival model to make full use of the DLT and PFS, defined as right‐censored competing risks outcomes, would be more informative in this setting.</p>
            </sec>
            <sec id="sim9591-sec-0004">
              <label>3</label>
              <title>METHODS</title>
              <sec id="sim9591-sec-0005">
                <label>3.1</label>
                <title>Problem formulation</title>
                <p>We consider a dose‐finding clinical trial where patients are followed up for DLT within an observation window <mml:math id="jats-math-2" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:msup><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msup><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:mrow></mml:math>, with the additional issue of a non negligible risk of treatment discontinuation due to disease progression, that precludes the complete and reliable assessment of DLT. In this time‐to‐event framework in oncology, data are collected as dates and <mml:math id="jats-math-3" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:mrow></mml:math> is defined in days, resulting in <mml:math id="jats-math-4" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msup><mml:mo>&gt;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mrow></mml:math>. During the trial, an aggravation of the patient status may occur, related to the progression of the malignancy, leading to treatment discontinuation in order to propose alternative therapies, if available. Similarly, patients who experience toxicity are generally dose reduced or discontinued and are inconsistently followed for efficacy or progression. In this setting, DLT and progression are competing events within <mml:math id="jats-math-5" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mo stretchy="false">[</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:msup><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msup><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:mrow></mml:math>, since both result in trial or treatment discontinuation. Consequently, by time <mml:math id="jats-math-6" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:mrow></mml:math>, patient can experience one of these three outcomes within the trial: “DLT,” “disease progression,” and “neither DLT nor progression.” Death is considered as a DLT if related to the toxicity and as progression otherwise. Note that we assume no other cause of treatment discontinuation, and no censoring due to lost to follow‐up, since it is unlikely in a oncology dose‐finding trial, where patients are usually closely followed and in advanced stages of their disease.</p>
                <p>Let <mml:math id="jats-math-7" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>N</mml:mi></mml:mrow></mml:mrow></mml:math>, be the maximum sample size of the trial, <mml:math id="jats-math-8" display="inline" overflow="scroll"><mml:mi>𝒟</mml:mi><mml:mo>=</mml:mo><mml:mo stretchy="false">{</mml:mo><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi>…</mml:mi><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>J</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">}</mml:mo></mml:math> the set of <mml:math id="jats-math-9" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>J</mml:mi></mml:mrow></mml:mrow></mml:math> doses of the new drug investigated in the trial. The goal of our proposed design is to identify a dose that optimizes the efficacy outcome, among tolerable doses. First, we define the set of tolerable doses, <mml:math id="jats-math-10" display="inline" overflow="scroll"><mml:mrow><mml:mi>𝒜</mml:mi></mml:mrow></mml:math>, as those dose levels at or below the MTD, defined as the dose with toxicity probability, <mml:math id="jats-math-11" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math> closest to the target <mml:math id="jats-math-12" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mtext>DLT</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>.
<disp-formula id="sim9591-disp-0001"><label>(1)</label><mml:math id="jats-math-13" display="block" overflow="scroll"><mml:mi>𝒜</mml:mi><mml:mo>=</mml:mo><mml:mo stretchy="false">{</mml:mo><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>∈</mml:mo><mml:mi>𝒟</mml:mi><mml:mo>:</mml:mo><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>≤</mml:mo><mml:mi>arg</mml:mi><mml:munder><mml:mrow><mml:mi>min</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>∈</mml:mo><mml:mi>𝒟</mml:mi></mml:mrow></mml:munder><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo form="prefix">−</mml:mo><mml:msub><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mtext>DLT</mml:mtext></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:mo stretchy="false">}</mml:mo><mml:mo>.</mml:mo></mml:math></disp-formula>
Then, we incorporate information on time‐to‐progression to identify the “optimal” dose (OD), <mml:math id="jats-math-14" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>ν</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>. We define the OD as the dose level(s) with minimum progression risk, among <mml:math id="jats-math-15" display="inline" overflow="scroll"><mml:mrow><mml:mi>𝒜</mml:mi></mml:mrow></mml:math>, the acceptable set of doses:
<disp-formula id="sim9591-disp-0002"><label>(2)</label><mml:math id="jats-math-16" display="block" overflow="scroll"><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>ν</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>arg</mml:mi><mml:munder><mml:mrow><mml:mi>min</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>∈</mml:mo><mml:mi>𝒜</mml:mi></mml:mrow></mml:munder><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:math></disp-formula>
with <mml:math id="jats-math-17" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>p</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>, the probability of disease progression at time <mml:math id="jats-math-18" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:mrow></mml:math> for dose level <mml:math id="jats-math-19" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:mrow></mml:math>.</p>
              </sec>
              <sec id="sim9591-sec-0006">
                <label>3.2</label>
                <title>Survival model</title>
                <p>Given the setting described above, we use a competing risks framework<xref rid="sim9591-bib-0025" ref-type="bibr"><sup>25</sup></xref>, <xref rid="sim9591-bib-0026" ref-type="bibr"><sup>26</sup></xref> to model the probabilities of DLT and disease progression. Let <mml:math id="jats-math-20" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow></mml:mrow></mml:math> denote the time‐to‐failure and <mml:math id="jats-math-21" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:mrow></mml:math> the cause of failure, with <mml:math id="jats-math-22" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mrow></mml:math> for DLT and <mml:math id="jats-math-23" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:mrow></mml:math> for disease progression. We define <mml:math id="jats-math-24" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">x</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math>, the cause‐specific instantaneous, and <mml:math id="jats-math-25" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">Λ</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">x</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math>, the cumulative hazards of cause <mml:math id="jats-math-26" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:mrow></mml:math> at dose level <mml:math id="jats-math-27" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:mrow></mml:math>, with <mml:math id="jats-math-28" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">x</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>, the scaled dose obtained by substituting the initial guess of toxicity and progression probabilities.</p>
                <p>We model both competing event processes with exponential hazard distributions.<xref rid="sim9591-bib-0027" ref-type="bibr"><sup>27</sup></xref>, <xref rid="sim9591-bib-0028" ref-type="bibr"><sup>28</sup></xref> Specifically, we assume the cause‐specific hazard for DLT <mml:math id="jats-math-29" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mo>.</mml:mo><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math> is an increasing function of the dose:
<disp-formula id="sim9591-disp-0003"><label>(3)</label><mml:math id="jats-math-30" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">x</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>exp</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">x</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo form="prefix">×</mml:mo><mml:mi>exp</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo><mml:mspace width="0.3em"/><mml:mspace width="0.3em"/><mml:mtext>for</mml:mtext><mml:mspace width="0.3em"/><mml:mspace width="0.3em"/><mml:mi>j</mml:mi><mml:mo>∈</mml:mo><mml:mo stretchy="false">{</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>…</mml:mi><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mo stretchy="false">}</mml:mo><mml:mo>,</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula>
and define the cause‐specific hazard for progression <mml:math id="jats-math-31" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mo>.</mml:mo><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math> resulting in a decreasing function of the dose, as follows:
<disp-formula id="sim9591-disp-0004"><label>(4)</label><mml:math id="jats-math-32" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">x</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mi>exp</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mo form="prefix">−</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">x</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo form="prefix">×</mml:mo><mml:mi>exp</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">)</mml:mo><mml:mo>,</mml:mo><mml:mspace width="0.3em"/><mml:mspace width="0.3em"/><mml:mtext>for</mml:mtext><mml:mspace width="0.3em"/><mml:mspace width="0.3em"/><mml:mi>j</mml:mi><mml:mo>∈</mml:mo><mml:mo stretchy="false">{</mml:mo><mml:mn>1</mml:mn><mml:mo>,</mml:mo><mml:mi>…</mml:mi><mml:mo>,</mml:mo><mml:mi>m</mml:mi><mml:mo stretchy="false">}</mml:mo><mml:mo>,</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula>
where <mml:math id="jats-math-33" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math> and <mml:math id="jats-math-34" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math> are model parameters of the dose‐toxicity and dose‐progression relationships, respectively.</p>
                <p><mml:math id="jats-math-35" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mo>·</mml:mo><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math>, the cumulative incidence of event <mml:math id="jats-math-36" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:mrow></mml:math>, at time <mml:math id="jats-math-37" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:mrow></mml:math> for dose level <mml:math id="jats-math-38" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:mrow></mml:math>, that is, the subdistribution function depending on both DLT and progression, expresses the probability of failing from cause <mml:math id="jats-math-39" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:mrow></mml:math> at or before <mml:math id="jats-math-40" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:mrow></mml:math> with dose level <mml:math id="jats-math-41" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:mrow></mml:math>, as follows:
<disp-formula id="sim9591-disp-0005"><label>(5)</label><mml:math id="jats-math-42" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:msubsup><mml:mrow><mml:mo>∫</mml:mo></mml:mrow><mml:mrow><mml:mn>0</mml:mn></mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:msubsup><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo form="prefix">×</mml:mo><mml:mi>S</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>s</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mi>d</mml:mi><mml:mi>s</mml:mi><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo form="prefix">×</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:mn>1</mml:mn><mml:mo form="prefix">−</mml:mo><mml:mi>exp</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mo form="prefix">−</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo form="prefix">×</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:mrow></mml:math></disp-formula>
with <mml:math id="jats-math-43" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>S</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mi>exp</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mo form="prefix">−</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">Λ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">Λ</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math>, the event‐free survival, that is, the probability of not having experienced a failure, from any cause (DLT or disease progression), at time <mml:math id="jats-math-44" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>t</mml:mi></mml:mrow></mml:mrow></mml:math>.</p>
                <p>Given <mml:math id="jats-math-45" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>B</mml:mi><mml:mo>=</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math> and <mml:math id="jats-math-46" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>N</mml:mi></mml:mrow></mml:mrow></mml:math> included patients, the survival likelihood can be expressed as follows:
<disp-formula id="sim9591-disp-0006"><label>(6)</label><mml:math id="jats-math-47" display="block" overflow="scroll"><mml:msub><mml:mrow><mml:mi>L</mml:mi></mml:mrow><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold">C</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="bold">Y</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="bold">D</mml:mi><mml:mo stretchy="false">|</mml:mo><mml:mi>B</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:munderover><mml:mrow><mml:mo>∏</mml:mo></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>N</mml:mi></mml:mrow></mml:munderover><mml:msub><mml:mrow><mml:mi>f</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi>B</mml:mi><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>𝒟</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mi>I</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>Y</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup><mml:msub><mml:mrow><mml:mi>f</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi>B</mml:mi><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>𝒟</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mi>I</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>Y</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>2</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup><mml:mi>S</mml:mi><mml:msup><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>C</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi>B</mml:mi><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>𝒟</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:mi>I</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>Y</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:msup></mml:math></disp-formula>
with <mml:math id="jats-math-48" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>f</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math> the density function of <mml:math id="jats-math-49" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow></mml:mrow></mml:math>, the time‐to‐event <mml:math id="jats-math-50" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:mrow></mml:math>, <mml:math id="jats-math-51" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi mathvariant="bold">C</mml:mi></mml:mrow></mml:mrow></mml:math> the right‐censored failure time and <mml:math id="jats-math-52" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi mathvariant="bold">Y</mml:mi></mml:mrow></mml:mrow></mml:math> the observed outcome defined as <mml:math id="jats-math-53" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi mathvariant="bold">Y</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mrow></mml:math> when DLT occurs first, <mml:math id="jats-math-54" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi mathvariant="bold">Y</mml:mi><mml:mo>=</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:mrow></mml:math> when disease progression occurs first and <mml:math id="jats-math-55" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi mathvariant="bold">Y</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:mrow></mml:math> when neither DLT nor progression occurs within the observation window.</p>
                <p>Inference on cause‐specific hazards could be performed for DLT and disease progression separately, since the log‐likelihood factors into two pieces, one involving <mml:math id="jats-math-56" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math> and the other involving <mml:math id="jats-math-57" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>.<xref rid="sim9591-bib-0027" ref-type="bibr"><sup>27</sup></xref>, <xref rid="sim9591-bib-0028" ref-type="bibr"><sup>28</sup></xref> Given the set of doses <mml:math id="jats-math-58" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi mathvariant="bold">D</mml:mi></mml:mrow></mml:mrow></mml:math>, the likelihood <mml:math id="jats-math-59" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>L</mml:mi></mml:mrow><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:mi mathvariant="bold">C</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="bold">Y</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="bold">D</mml:mi><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math> and normal prior distributions <mml:math id="jats-math-60" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math> of <mml:math id="jats-math-61" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>, the posterior distributions for <mml:math id="jats-math-62" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math> for event <mml:math id="jats-math-63" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:mrow></mml:math> using Bayes inference is given by:
<disp-formula id="sim9591-disp-0007"><label>(7)</label><mml:math id="jats-math-64" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:mi mathvariant="bold">C</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="bold">Y</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="bold">D</mml:mi><mml:mo stretchy="false">)</mml:mo><mml:mo>∝</mml:mo><mml:msub><mml:mrow><mml:mi>L</mml:mi></mml:mrow><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold">C</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="bold">Y</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="bold">D</mml:mi><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>.</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula>
</p>
                <p>The posterior mean <mml:math id="jats-math-65" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mover accent="true"><mml:mrow><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>^</mml:mo></mml:mover></mml:mrow></mml:mrow></mml:math> can be plugged in Equations (<xref rid="sim9591-disp-0003" ref-type="disp-formula">3</xref>) to (<xref rid="sim9591-disp-0005" ref-type="disp-formula">5</xref>) to compute <mml:math id="jats-math-66" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mover accent="true"><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mo>^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math>, the mean estimated cumulative incidence of event <mml:math id="jats-math-67" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:mrow></mml:math> at each dose level <mml:math id="jats-math-68" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:mrow></mml:math>:
<disp-formula id="sim9591-disp-0008"><label>(8)</label><mml:math id="jats-math-69" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mover accent="true"><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mo>^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:msubsup><mml:mrow><mml:mo>∫</mml:mo></mml:mrow><mml:mrow><mml:mo form="prefix">−</mml:mo><mml:mi>∞</mml:mi></mml:mrow><mml:mrow><mml:mi>∞</mml:mi></mml:mrow></mml:msubsup><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:msub><mml:mrow><mml:mi>L</mml:mi></mml:mrow><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold">C</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="bold">Y</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="bold">D</mml:mi><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mi>ϕ</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mi>d</mml:mi><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msubsup><mml:mrow><mml:mo>∫</mml:mo></mml:mrow><mml:mrow><mml:mo form="prefix">−</mml:mo><mml:mi>∞</mml:mi></mml:mrow><mml:mrow><mml:mi>∞</mml:mi></mml:mrow></mml:msubsup><mml:msub><mml:mrow><mml:mi>L</mml:mi></mml:mrow><mml:mrow><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi mathvariant="bold">C</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="bold">Y</mml:mi><mml:mo>,</mml:mo><mml:mi mathvariant="bold">D</mml:mi><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mi mathvariant="normal">Φ</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mi>d</mml:mi><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mfrac><mml:mo>.</mml:mo></mml:mrow></mml:mrow></mml:math></disp-formula>
</p>
                <p>The toxicity and progression cumulative incidence estimates are then used to make decision regarding dose allocation as described in Section <xref rid="sim9591-sec-0007" ref-type="sec">3.3</xref>.</p>
              </sec>
              <sec id="sim9591-sec-0007">
                <label>3.3</label>
                <title>Dose‐finding algorithm</title>
                <p>Based on the aforementioned probability model, we propose a one‐stage dose‐finding trial using both toxicity and efficacy information in the dose‐assignment process with the goal to identify a dose that optimizes the efficacy outcome, that is, the time‐to‐progression among a set of acceptable doses, <mml:math id="jats-math-70" display="inline" overflow="scroll"><mml:msub><mml:mrow><mml:mi>𝒜</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:math>, as defined below.</p>
                <p>After the <mml:math id="jats-math-71" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:mrow></mml:math>th patient being included, the set of acceptable doses (in terms of DLT), that excludes overly toxic doses, is estimated as follows:
<disp-formula id="sim9591-disp-0009"><label>(9)</label><mml:math id="jats-math-72" display="block" overflow="scroll"><mml:msub><mml:mrow><mml:mi>𝒜</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mo stretchy="false">{</mml:mo><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>∈</mml:mo><mml:mi>𝒟</mml:mi><mml:mo>:</mml:mo><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>≤</mml:mo><mml:mi>arg</mml:mi><mml:munder><mml:mrow><mml:mi>min</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>∈</mml:mo><mml:mi>𝒟</mml:mi></mml:mrow></mml:munder><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mrow><mml:mover accent="true"><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mo>^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msup><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo form="prefix">−</mml:mo><mml:msub><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mtext>DLT</mml:mtext></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:mo stretchy="false">}</mml:mo></mml:math></disp-formula>
with <mml:math id="jats-math-73" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mover accent="true"><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mo>^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msup><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math>, the vector of estimates of choice for <mml:math id="jats-math-74" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mi>t</mml:mi><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math> at each dose level, given available data.</p>
                <p>The set of good doses, <mml:math id="jats-math-75" display="inline" overflow="scroll"><mml:msub><mml:mrow><mml:mi>𝒢</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:math>, is then defined as the dose levels among <mml:math id="jats-math-76" display="inline" overflow="scroll"><mml:msub><mml:mrow><mml:mi>𝒜</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:math> with an estimated incidence of progression at time t<mml:math id="jats-math-77" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msup><mml:mo> </mml:mo><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:mrow></mml:math>, <mml:math id="jats-math-78" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mover accent="true"><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mo>^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msup><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math>, lying within a range <mml:math id="jats-math-79" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>ϵ</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math> from the minimum estimate:
<disp-formula id="sim9591-disp-0010"><label>(10)</label><mml:math id="jats-math-80" display="block" overflow="scroll"><mml:msub><mml:mrow><mml:mi>𝒢</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mo stretchy="false">{</mml:mo><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>∈</mml:mo><mml:msub><mml:mrow><mml:mi>𝒜</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub><mml:mo>:</mml:mo><mml:msub><mml:mrow><mml:mover accent="true"><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mo>^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msup><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo form="prefix">−</mml:mo><mml:mi>min</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mover accent="true"><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mo>^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msup><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo stretchy="false">)</mml:mo><mml:mo>≤</mml:mo><mml:msub><mml:mrow><mml:mi>ϵ</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">}</mml:mo><mml:mo>,</mml:mo></mml:math></disp-formula>
where <mml:math id="jats-math-81" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>ϵ</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math> is a fixed known parameter that can be tuned based on clinical considerations related to the risk of progression under the standard of care.</p>
                <p>To choose the dose allocated to the upcoming <mml:math id="jats-math-82" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>i</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math>th patient (or cohort) among the set of good doses <mml:math id="jats-math-83" display="inline" overflow="scroll"><mml:msub><mml:mrow><mml:mi>𝒢</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:math>, we use an adaptive randomization algorithm,<xref rid="sim9591-bib-0017" ref-type="bibr"><sup>17</sup></xref> unless only a single good dose level is identified. Otherwise, randomization across those good doses prevents the method from getting “stuck” on a single dose that has been tried early in the trial. Based on the estimated cumulative incidence of progression, <mml:math id="jats-math-84" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mover accent="true"><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mo>^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msup><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math>, for doses <mml:math id="jats-math-85" display="inline" overflow="scroll"><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>∈</mml:mo><mml:msub><mml:mrow><mml:mi>𝒢</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:math>, randomization probability <mml:math id="jats-math-86" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math> is computed as follows:
<disp-formula id="sim9591-disp-0011"><label>(11)</label><mml:math id="jats-math-87" display="block" overflow="scroll"><mml:msub><mml:mrow><mml:mi>ℛ</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn><mml:mo form="prefix">−</mml:mo><mml:msub><mml:mrow><mml:mover accent="true"><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mo>^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msup><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mo>∑</mml:mo></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>∈</mml:mo><mml:msub><mml:mrow><mml:mi>𝒢</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:msub><mml:mn>1</mml:mn><mml:mo form="prefix">−</mml:mo><mml:msub><mml:mrow><mml:mover accent="true"><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mo>^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msup><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac><mml:mo>,</mml:mo></mml:math></disp-formula>
and is used to allocate the next patient or cohort to dose <mml:math id="jats-math-88" display="inline" overflow="scroll"><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>∈</mml:mo><mml:msub><mml:mrow><mml:mi>𝒢</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi></mml:mrow></mml:msub></mml:math> with probability <mml:math id="jats-math-89" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>R</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>.</p>
                <p>The trial ended either when the maximum sample size <mml:math id="jats-math-90" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>N</mml:mi></mml:mrow></mml:mrow></mml:math> has been reached, or for safety decisions, that is, when the posterior probability of <mml:math id="jats-math-91" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mn>11</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mo>⋆</mml:mo></mml:mrow></mml:msup><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math> exceeding the target <mml:math id="jats-math-92" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mtext>DLT</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math> is at least 0.95.<xref rid="sim9591-bib-0029" ref-type="bibr"><sup>29</sup></xref> In the latter, we consider all doses as over‐toxic and terminate the trial. If the maximum sample size <mml:math id="jats-math-93" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>N</mml:mi></mml:mrow></mml:mrow></mml:math> has been reached and the follow‐up completed for every patient, the OD, <mml:math id="jats-math-94" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mover accent="true"><mml:mrow><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>ν</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>^</mml:mo></mml:mover></mml:mrow></mml:mrow></mml:math>, is then estimated as the dose with the minimum estimated cumulative incidence of progression among the acceptable set of doses, <mml:math id="jats-math-95" display="inline" overflow="scroll"><mml:msubsup><mml:mrow><mml:mi>𝒜</mml:mi></mml:mrow><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msubsup></mml:math>:
<disp-formula id="sim9591-disp-0012"><label>(12)</label><mml:math id="jats-math-96" display="block" overflow="scroll"><mml:mover accent="true"><mml:mrow><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>ν</mml:mi></mml:mrow></mml:msub></mml:mrow><mml:mo>^</mml:mo></mml:mover><mml:mo>=</mml:mo><mml:mi>arg</mml:mi><mml:munder><mml:mrow><mml:mi>min</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>∈</mml:mo><mml:msubsup><mml:mrow><mml:mi>𝒜</mml:mi></mml:mrow><mml:mrow><mml:mi>N</mml:mi></mml:mrow><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msubsup></mml:mrow></mml:munder><mml:msub><mml:mrow><mml:mover accent="true"><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mo>^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msup><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>.</mml:mo></mml:math></disp-formula>
</p>
                <p>An optional preliminary stage centered on the dose‐toxicity relationship could also be conducted before the optimization presented above if clinical considerations justify increased caution related to patients safety at the beginning of the trial. More precisely, we propose to first use a continual reassessment method (CRM)‐like approach, in order to guide sequential dose‐assignments of the first subset of <mml:math id="jats-math-97" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mo form="prefix">×</mml:mo><mml:mi>N</mml:mi></mml:mrow></mml:mrow></mml:math> patients of the total sample size <mml:math id="jats-math-98" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>N</mml:mi></mml:mrow></mml:mrow></mml:math>, with <mml:math id="jats-math-99" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mo>∈</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:mrow></mml:math> a design parameter to be pre‐specified when planning the trial. Relying on the monotonicity assumption of the dose‐toxicity relationship, the objective of this first stage is to identify the dose with a cumulative incidence of DLT at time t<mml:math id="jats-math-100" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msup><mml:mo> </mml:mo><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:mrow></mml:math>, <mml:math id="jats-math-101" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:mo>·</mml:mo><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math>, closest to a pre‐specified target <mml:math id="jats-math-102" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mtext>DLT</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>. At this stage, an upcoming <mml:math id="jats-math-103" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:mi>i</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math>th cohort of patients is therefore allocated to dose <mml:math id="jats-math-104" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msubsup><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msubsup></mml:mrow></mml:mrow></mml:math> in the following way:
<disp-formula id="sim9591-disp-0013"><label>(13)</label><mml:math id="jats-math-105" display="block" overflow="scroll"><mml:msubsup><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow><mml:mrow><mml:mi>i</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msubsup><mml:mo>=</mml:mo><mml:mi>arg</mml:mi><mml:munder><mml:mrow><mml:mi>min</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>∈</mml:mo><mml:mi>𝒟</mml:mi></mml:mrow></mml:munder><mml:mo stretchy="false">|</mml:mo><mml:msub><mml:mrow><mml:mover accent="true"><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mo>^</mml:mo></mml:mover></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msup><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo form="prefix">−</mml:mo><mml:msub><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mtext>DLT</mml:mtext></mml:mrow></mml:msub><mml:mo stretchy="false">|</mml:mo><mml:mo>.</mml:mo></mml:math></disp-formula>
</p>
                <p>After the <mml:math id="jats-math-106" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>N</mml:mi></mml:mrow></mml:mrow></mml:math> patients have been included, we incorporate information on the dose‐progression relationship in the dose‐assignment process as presented above.</p>
              </sec>
            </sec>
            <sec id="sim9591-sec-0008">
              <label>4</label>
              <title>SIMULATION STUDY</title>
              <p>We conducted a comprehensive simulation study to explore the properties of our proposed Surv‐CRM‐12 design across a variety of settings. The operating characteristics of the Surv‐CRM‐12 design were compared with that of the TITE‐BOIN‐ET<xref rid="sim9591-bib-0022" ref-type="bibr"><sup>22</sup></xref> approach. Indeed, the objective of the TITE‐BOIN‐ET is also to determine the OD defined as the dose that maximizes the efficacy probability satisfying a tolerability constraint. Additionally, performances of the proposed design were assessed using a nonparametric benchmark approach.<xref rid="sim9591-bib-0030" ref-type="bibr"><sup>30</sup></xref>, <xref rid="sim9591-bib-0031" ref-type="bibr"><sup>31</sup></xref>
</p>
              <sec id="sim9591-sec-0009">
                <label>4.1</label>
                <title>Setting</title>
                <p>In line with our motivating example, we set the observation window <mml:math id="jats-math-107" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:mn>42</mml:mn></mml:mrow></mml:mrow></mml:math> days. We considered <mml:math id="jats-math-108" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>J</mml:mi><mml:mo>=</mml:mo><mml:mn>5</mml:mn></mml:mrow></mml:mrow></mml:math> candidate dose levels, and, within the time window <mml:math id="jats-math-109" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:mrow></mml:math>, a target toxicity probability of DLT at <mml:math id="jats-math-110" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mtext>DLT</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mo>.</mml:mo><mml:mn>25</mml:mn></mml:mrow></mml:mrow></mml:math> and a threshold to define the good doses, <mml:math id="jats-math-111" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>ϵ</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mo>.</mml:mo><mml:mn>10</mml:mn></mml:mrow></mml:mrow></mml:math>. We simulated patient accrual using a Poisson process with an expected accrual rate of 4 patients in 42 days. The total sample size was set at <mml:math id="jats-math-112" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>N</mml:mi><mml:mo>=</mml:mo><mml:mn>45</mml:mn></mml:mrow></mml:mrow></mml:math> using a single stage design for dose assignment (ie, <mml:math id="jats-math-113" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mi>N</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn></mml:mrow></mml:mrow></mml:math>). Simulated trials were initiated with the first dose level, <mml:math id="jats-math-114" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>. The cohort size was 1, and no dose skipping was allowed.</p>
                <p>To assess the robustness of our proposed method, sensitivity analyses were also conducted. We first conducted a simulation study to examine the sensitivity of our design to the specification of priors. We considered normal priors with different SDs for the unknown parameters <mml:math id="jats-math-115" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math> and <mml:math id="jats-math-116" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math> under each scenarios. We also varied the sample size from <mml:math id="jats-math-117" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>N</mml:mi><mml:mo>=</mml:mo><mml:mn>30</mml:mn></mml:mrow></mml:mrow></mml:math> to <mml:math id="jats-math-118" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>N</mml:mi><mml:mo>=</mml:mo><mml:mn>150</mml:mn></mml:mrow></mml:mrow></mml:math>, and the number of patients allocated to the first optional toxicity‐centered stage, <mml:math id="jats-math-119" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mo>.</mml:mo><mml:mn>33</mml:mn></mml:mrow></mml:mrow></mml:math> and <mml:math id="jats-math-120" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>r</mml:mi><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mo>.</mml:mo><mml:mn>5</mml:mn></mml:mrow></mml:mrow></mml:math>. Furthermore, we also evaluated our method in the case of correlated time‐to‐event data using the Clayton model following Yuan and Yin's approach.<xref rid="sim9591-bib-0016" ref-type="bibr"><sup>16</sup></xref>
</p>
              </sec>
              <sec id="sim9591-sec-0010">
                <label>4.2</label>
                <title>Calibration of model parameters</title>
                <p>To jointly calibrate the skeletons and the prior variance of the parameters <mml:math id="jats-math-121" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math> and <mml:math id="jats-math-122" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>, we extended the calibration procedure using the concepts of the least informative prior variance and indifference intervals developed by Lee and Cheung.<xref rid="sim9591-bib-0032" ref-type="bibr"><sup>32</sup></xref> Specifically, two design skeletons, for toxicity and progression respectively, were calibrated using the indifference interval approach,<xref rid="sim9591-bib-0033" ref-type="bibr"><sup>33</sup></xref>, <xref rid="sim9591-bib-0034" ref-type="bibr"><sup>34</sup></xref> using the working models of the proposed design (Equation <xref rid="sim9591-disp-0005" ref-type="disp-formula">5</xref>).</p>
                <p>Let <mml:math id="jats-math-123" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>θ</mml:mi></mml:mrow><mml:mrow><mml:mtext>DLT</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math> be the target probability of toxicity and <mml:math id="jats-math-124" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>θ</mml:mi></mml:mrow><mml:mrow><mml:mtext>PROG</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math> the expected probability of progression at the best guess or expected OD <mml:math id="jats-math-125" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>ν</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>, at <mml:math id="jats-math-126" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:mrow></mml:math>. Let <mml:math id="jats-math-127" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi mathvariant="normal">Θ</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:msub><mml:mrow><mml:mi>b</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>b</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mi>J</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:mrow></mml:math> be the parameter space for the working model of event <mml:math id="jats-math-128" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:mrow></mml:math> (ie, <mml:math id="jats-math-129" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>b</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub><mml:mo>∈</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">Θ</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math> with <mml:math id="jats-math-130" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mrow></mml:math> for toxicity and <mml:math id="jats-math-131" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>2</mml:mn></mml:mrow></mml:mrow></mml:math> for progression). We define the indifference intervals for event <mml:math id="jats-math-132" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>k</mml:mi></mml:mrow></mml:mrow></mml:math>, <mml:math id="jats-math-133" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>ℋ</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mo stretchy="false">[</mml:mo><mml:msub><mml:mrow><mml:mi>b</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>b</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math>, <mml:math id="jats-math-134" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>ℋ</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>b</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>b</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mi>j</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math> for <mml:math id="jats-math-135" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mi>…</mml:mi><mml:mo>,</mml:mo><mml:mi>J</mml:mi><mml:mo form="prefix">−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mrow></mml:math> and <mml:math id="jats-math-136" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>ℋ</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mi>J</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>b</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mi>J</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>b</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mi>J</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">]</mml:mo></mml:mrow></mml:mrow></mml:math>, where <mml:math id="jats-math-137" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>B</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>b</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>b</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math> solves
<disp-formula id="sim9591-disp-0014"><mml:math id="jats-math-138" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msup><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi><mml:mo form="prefix">−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>;</mml:mo><mml:msub><mml:mrow><mml:mi>B</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mi>k</mml:mi><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">(</mml:mo><mml:msup><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msup><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>;</mml:mo><mml:msub><mml:mrow><mml:mi>B</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mo>=</mml:mo><mml:mfenced separators="" open="{" close=""><mml:mrow><mml:mtable><mml:mtr><mml:mtd class="array"><mml:mn>2</mml:mn><mml:msub><mml:mrow><mml:mi>θ</mml:mi></mml:mrow><mml:mrow><mml:mtext>DLT</mml:mtext></mml:mrow></mml:msub></mml:mtd><mml:mtd class="array"><mml:mtext>for</mml:mtext></mml:mtd><mml:mtd class="array"><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>1</mml:mn></mml:mtd></mml:mtr><mml:mtr><mml:mtd class="array"><mml:mn>2</mml:mn><mml:msub><mml:mrow><mml:mi>θ</mml:mi></mml:mrow><mml:mrow><mml:mtext>PROG</mml:mtext></mml:mrow></mml:msub></mml:mtd><mml:mtd class="array"><mml:mtext>for</mml:mtext></mml:mtd><mml:mtd class="array"><mml:mi>k</mml:mi><mml:mo>=</mml:mo><mml:mn>2</mml:mn></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:mfenced></mml:mrow></mml:mrow></mml:math></disp-formula>
with <mml:math id="jats-math-139" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">x</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi mathvariant="normal">x</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math> the scaled doses.</p>
                <p>By specifying a common half‐width indifference interval for all dose levels, that is <mml:math id="jats-math-140" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>δ</mml:mi></mml:mrow></mml:mrow></mml:math>, <mml:math id="jats-math-141" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>,</mml:mo><mml:mi>…</mml:mi><mml:msub><mml:mrow><mml:mi>X</mml:mi></mml:mrow><mml:mrow><mml:mi>J</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math> can be obtained recursively using the approach presented in Lee and Cheung,<xref rid="sim9591-bib-0033" ref-type="bibr"><sup>33</sup></xref> as described below.
<disp-formula id="sim9591-disp-0015"><mml:math id="jats-math-142" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mtable class="align" columnalign="left"><mml:mtr><mml:mtd class="align-1"><mml:msub><mml:mrow><mml:mi mathvariant="normal">x</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mi>j</mml:mi><mml:mo form="prefix">−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mtd><mml:mtd class="align-2"><mml:mo>=</mml:mo><mml:mi>log</mml:mi><mml:mfenced separators="" open="(" close=")"><mml:mrow><mml:mfrac><mml:mrow><mml:mo form="prefix">−</mml:mo><mml:mi>log</mml:mi><mml:mo stretchy="true">{</mml:mo><mml:mn>1</mml:mn><mml:mo form="prefix">−</mml:mo><mml:mo stretchy="true">(</mml:mo><mml:msub><mml:mrow><mml:mi>θ</mml:mi></mml:mrow><mml:mrow><mml:mtext>DLT</mml:mtext></mml:mrow></mml:msub><mml:mo form="prefix">−</mml:mo><mml:mi>δ</mml:mi><mml:mo stretchy="true">)</mml:mo><mml:mo form="prefix">−</mml:mo><mml:mo stretchy="true">(</mml:mo><mml:msub><mml:mrow><mml:mi>θ</mml:mi></mml:mrow><mml:mrow><mml:mtext>PROG</mml:mtext></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>δ</mml:mi><mml:mo stretchy="true">)</mml:mo><mml:mo stretchy="true">}</mml:mo></mml:mrow><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>θ</mml:mi></mml:mrow><mml:mrow><mml:mtext>PROG</mml:mtext></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>δ</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>θ</mml:mi></mml:mrow><mml:mrow><mml:mtext>DLT</mml:mtext></mml:mrow></mml:msub><mml:mo form="prefix">−</mml:mo><mml:mi>δ</mml:mi></mml:mrow></mml:mfrac><mml:mo stretchy="true">)</mml:mo><mml:mspace width="0.3em"/><mml:mo form="prefix">×</mml:mo><mml:mspace width="0.3em"/><mml:msup><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:mfrac></mml:mrow></mml:mfenced><mml:mo form="prefix">×</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>exp</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>b</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac><mml:mo>,</mml:mo><mml:mspace width="0em"/></mml:mtd><mml:mtd/><mml:mtd/></mml:mtr><mml:mtr><mml:mtd class="align-1"><mml:msub><mml:mrow><mml:mi mathvariant="normal">x</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>j</mml:mi><mml:mo form="prefix">−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mtd><mml:mtd class="align-2"><mml:mo>=</mml:mo><mml:mo form="prefix">−</mml:mo><mml:mi>log</mml:mi><mml:mfenced separators="" open="(" close=")"><mml:mrow><mml:mfrac><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:msub><mml:mrow><mml:mi>θ</mml:mi></mml:mrow><mml:mrow><mml:mtext>PROG</mml:mtext></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>δ</mml:mi><mml:mo stretchy="true">)</mml:mo><mml:mspace width="0.3em"/><mml:mo form="prefix">×</mml:mo><mml:mspace width="0.3em"/><mml:mi>exp</mml:mi><mml:mo stretchy="true">(</mml:mo><mml:mi>exp</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>b</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mspace width="0.3em"/><mml:mo form="prefix">×</mml:mo><mml:mspace width="0.3em"/><mml:msub><mml:mrow><mml:mi mathvariant="normal">x</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mi>j</mml:mi><mml:mo form="prefix">−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>θ</mml:mi></mml:mrow><mml:mrow><mml:mtext>DLT</mml:mtext></mml:mrow></mml:msub><mml:mo form="prefix">−</mml:mo><mml:mi>δ</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:mfenced><mml:mo form="prefix">×</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>exp</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>b</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>j</mml:mi></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac><mml:mo>,</mml:mo><mml:mspace width="0em"/></mml:mtd><mml:mtd/><mml:mtd/></mml:mtr></mml:mtable></mml:mrow></mml:mrow></mml:math></disp-formula>
for <mml:math id="jats-math-143" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mn>2</mml:mn><mml:mo>,</mml:mo><mml:mi>…</mml:mi><mml:mo>,</mml:mo><mml:mi>ν</mml:mi></mml:mrow></mml:mrow></mml:math>,
<disp-formula id="sim9591-disp-0016"><mml:math id="jats-math-144" display="block" overflow="scroll"><mml:mrow><mml:mrow><mml:mtable class="align" columnalign="left"><mml:mtr><mml:mtd class="align-1"><mml:msub><mml:mrow><mml:mi mathvariant="normal">x</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mi>j</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mtd><mml:mtd class="align-2"><mml:mo>=</mml:mo><mml:mi>log</mml:mi><mml:mfenced separators="" open="(" close=")"><mml:mrow><mml:mfrac><mml:mrow><mml:mo form="prefix">−</mml:mo><mml:mi>log</mml:mi><mml:mo stretchy="true">{</mml:mo><mml:mn>1</mml:mn><mml:mo form="prefix">−</mml:mo><mml:mo stretchy="true">(</mml:mo><mml:msub><mml:mrow><mml:mi>θ</mml:mi></mml:mrow><mml:mrow><mml:mtext>DLT</mml:mtext></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>δ</mml:mi><mml:mo stretchy="true">)</mml:mo><mml:mo form="prefix">−</mml:mo><mml:mo stretchy="true">(</mml:mo><mml:msub><mml:mrow><mml:mi>θ</mml:mi></mml:mrow><mml:mrow><mml:mtext>PROG</mml:mtext></mml:mrow></mml:msub><mml:mo form="prefix">−</mml:mo><mml:mi>δ</mml:mi><mml:mo stretchy="true">)</mml:mo><mml:mo stretchy="true">}</mml:mo></mml:mrow><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:mn>1</mml:mn><mml:mo>+</mml:mo><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>θ</mml:mi></mml:mrow><mml:mrow><mml:mtext>PROG</mml:mtext></mml:mrow></mml:msub><mml:mo form="prefix">−</mml:mo><mml:mi>δ</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>θ</mml:mi></mml:mrow><mml:mrow><mml:mtext>DLT</mml:mtext></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>δ</mml:mi></mml:mrow></mml:mfrac><mml:mo stretchy="true">)</mml:mo><mml:mspace width="0.3em"/><mml:mo form="prefix">×</mml:mo><mml:mspace width="0.3em"/><mml:msup><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:mfrac></mml:mrow></mml:mfenced><mml:mo form="prefix">×</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>exp</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>b</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mi>j</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac><mml:mo>,</mml:mo><mml:mspace width="0em"/></mml:mtd><mml:mtd/><mml:mtd/></mml:mtr><mml:mtr><mml:mtd class="align-1"><mml:msub><mml:mrow><mml:mi mathvariant="normal">x</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>j</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mtd><mml:mtd class="align-2"><mml:mo>=</mml:mo><mml:mo form="prefix">−</mml:mo><mml:mi>log</mml:mi><mml:mfenced separators="" open="(" close=")"><mml:mrow><mml:mfrac><mml:mrow><mml:mo stretchy="true">(</mml:mo><mml:msub><mml:mrow><mml:mi>θ</mml:mi></mml:mrow><mml:mrow><mml:mtext>PROG</mml:mtext></mml:mrow></mml:msub><mml:mo form="prefix">−</mml:mo><mml:mi>δ</mml:mi><mml:mo stretchy="true">)</mml:mo><mml:mspace width="0.3em"/><mml:mo form="prefix">×</mml:mo><mml:mspace width="0.3em"/><mml:mi>exp</mml:mi><mml:mo stretchy="true">(</mml:mo><mml:mi>exp</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>b</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mi>j</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo><mml:mspace width="0.3em"/><mml:mo form="prefix">×</mml:mo><mml:mspace width="0.3em"/><mml:msub><mml:mrow><mml:mi mathvariant="normal">x</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mi>j</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="true">)</mml:mo></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>θ</mml:mi></mml:mrow><mml:mrow><mml:mtext>DLT</mml:mtext></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:mi>δ</mml:mi></mml:mrow></mml:mfrac></mml:mrow></mml:mfenced><mml:mo form="prefix">×</mml:mo><mml:mfrac><mml:mrow><mml:mn>1</mml:mn></mml:mrow><mml:mrow><mml:mi>exp</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>b</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn><mml:mi>j</mml:mi><mml:mo>+</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mfrac><mml:mo>,</mml:mo><mml:mspace width="0em"/></mml:mtd><mml:mtd/><mml:mtd/></mml:mtr></mml:mtable></mml:mrow></mml:mrow></mml:math></disp-formula>
for <mml:math id="jats-math-145" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>j</mml:mi><mml:mo>=</mml:mo><mml:mi>ν</mml:mi><mml:mo>,</mml:mo><mml:mi>…</mml:mi><mml:mo>,</mml:mo><mml:mi>J</mml:mi><mml:mo form="prefix">−</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mrow></mml:math>.</p>
                <p>Then, the least informative prior normal SD for <mml:math id="jats-math-146" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>, <mml:math id="jats-math-147" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msubsup><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi>L</mml:mi><mml:mi>I</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mrow></mml:math>, can be obtained for a given <mml:math id="jats-math-148" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>δ</mml:mi></mml:mrow></mml:mrow></mml:math> using the toxicity working model with the least informative prior approach described in Lee and Cheung.<xref rid="sim9591-bib-0032" ref-type="bibr"><sup>32</sup></xref> The least informative SD is the one such that the prior probability of selecting a dose corresponds to a uniform distribution among the candidate dose levels (ie, 1/J). We assume the prior normal SD for <mml:math id="jats-math-149" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math> is equal to the SD of <mml:math id="jats-math-150" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>.</p>
                <p>Based on this approach, we calibrated both skeletons (toxicity and progression) and the prior variance for the working models parameters, <mml:math id="jats-math-151" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math> and <mml:math id="jats-math-152" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>, in our trial setting. We first evaluated the performances of the Surv‐CRM‐12 across values of <mml:math id="jats-math-153" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>δ</mml:mi></mml:mrow></mml:mrow></mml:math> based on a set of calibration scenarios where the true probabilities of DLT and progression followed plateau configurations as described by Lee and Cheung.<xref rid="sim9591-bib-0033" ref-type="bibr"><sup>33</sup></xref> The algorithm was implemented with <mml:math id="jats-math-154" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msup><mml:mo>=</mml:mo><mml:mn>42</mml:mn></mml:mrow></mml:mrow></mml:math>, a target toxicity probability <mml:math id="jats-math-155" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>θ</mml:mi></mml:mrow><mml:mrow><mml:mtext>DLT</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mo>.</mml:mo><mml:mn>25</mml:mn></mml:mrow></mml:mrow></mml:math> and an expected progression probability <mml:math id="jats-math-156" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>θ</mml:mi></mml:mrow><mml:mrow><mml:mtext>PROG</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mo>.</mml:mo><mml:mn>40</mml:mn></mml:mrow></mml:mrow></mml:math> at <mml:math id="jats-math-157" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mi>ν</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>, <mml:math id="jats-math-158" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>J</mml:mi><mml:mo>=</mml:mo><mml:mn>5</mml:mn></mml:mrow></mml:mrow></mml:math> dose levels and dose level 3 as the OD. We iterated <mml:math id="jats-math-159" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>δ</mml:mi></mml:mrow></mml:mrow></mml:math> from 0.01 to 0.6<mml:math id="jats-math-160" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>θ</mml:mi></mml:mrow><mml:mrow><mml:mtext>DLT</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math> in a discrete domain with a grid half‐width of 0.01 and calculate <mml:math id="jats-math-161" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msubsup><mml:mrow><mml:mi>σ</mml:mi></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>β</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:mi>L</mml:mi><mml:mi>I</mml:mi></mml:mrow></mml:msubsup></mml:mrow></mml:mrow></mml:math> for each <mml:math id="jats-math-162" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>δ</mml:mi></mml:mrow></mml:mrow></mml:math> value. Based on 2000 simulations, on a set of calibration scenarios of the plateau configuration defined following,<xref rid="sim9591-bib-0033" ref-type="bibr"><sup>33</sup></xref> we set the half‐width of the indifference interval at 0.07 and the prior SD at 0.379, as providing the highest average probability of correct selection (PCS) across the calibration scenarios, corresponding to the following skeletons for toxicity and progression respectively {0.055, 0.130, 0.250, 0.406, 0.571} and {0.666, 0.541, 0.400, 0.266, 0.158}. As a sensitivity analysis, we also considered fixing the SD at <mml:math id="jats-math-163" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msqrt><mml:mrow><mml:mn>1</mml:mn><mml:mo>.</mml:mo><mml:mn>34</mml:mn></mml:mrow></mml:msqrt></mml:mrow></mml:mrow></mml:math>
<xref rid="sim9591-bib-0035" ref-type="bibr"><sup>35</sup></xref> and only calibrating the two skeletons using the indifference interval approach.</p>
              </sec>
              <sec id="sim9591-sec-0011">
                <label>4.3</label>
                <title>Simulated scenarios</title>
                <p>Several non‐parametric scenarios of dose‐toxicity and dose‐progression relationships were examined (Figure <xref rid="sim9591-fig-0001" ref-type="fig">1</xref>). They differed in terms of the cumulative incidences of DLT and disease progression at time <mml:math id="jats-math-164" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mo>⋆</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:mrow></mml:math> by dose level and encompassed different realistic shapes of dose‐DLT and dose‐progression relationships.</p>
                <fig position="float" fig-type="FIGURE" id="sim9591-fig-0001">
                  <label>FIGURE 1</label>
                  <caption>
                    <p>Simulation scenarios: True cumulative incidences of DLT (solid line) and progression (dashed line) at time <mml:math id="jats-math-165" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:mrow></mml:math> for each dose level, D1 to D5. OD, optimal dose</p>
                  </caption>
                  <graphic xlink:href="SIM-41-5753-g001" position="anchor" id="jats-graphic-1">
                    <alt-text>SIM-9591-FIG-0001-b</alt-text>
                  </graphic>
                </fig>
                <p>The first seven scenarios (Sc) had varying optimal and acceptable doses in position over the range of the five candidate dose levels: for Sc1 to Sc3, Sc6, Sc9, and Sc11, acceptable doses were <mml:math id="jats-math-166" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math> to <mml:math id="jats-math-167" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>3</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>; for Sc4, Sc7, and Sc8, <mml:math id="jats-math-168" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math> to <mml:math id="jats-math-169" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>4</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>, and for Sc5 and Sc10, <mml:math id="jats-math-170" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math> to <mml:math id="jats-math-171" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>5</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>. Scenarios also differed regarding the shape of dose‐progression relationships including high (Sc9‐Sc11), low (Sc2) and moderate risk of disease progression, steeper slope (Sc1‐Sc5) and plateau (Sc6 and Sc7). We also examined operating characteristics of our proposed design in comparison with the benchmark approach and the TITE‐BOIN‐ET design on a U‐shape dose‐progression scenario (Sc8). To avoid cherry‐picked scenarios that favor the proposed design, we examined four additional scenarios previously used in the study by Takeda et al<xref rid="sim9591-bib-0022" ref-type="bibr"><sup>22</sup></xref> (Sc9‐Sc12). For simplicity, we defined the true cumulative incidence of progression at time <mml:math id="jats-math-172" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:mrow></mml:math> as the complementary of the true probability of efficacy.</p>
                <p>Trial data were generated according to a tolerance profile procedure<xref rid="sim9591-bib-0030" ref-type="bibr"><sup>30</sup></xref>, <xref rid="sim9591-bib-0031" ref-type="bibr"><sup>31</sup></xref> drawn from a uniform distribution <mml:math id="jats-math-173" display="inline" overflow="scroll"><mml:mi>𝕌</mml:mi><mml:mo stretchy="false">(</mml:mo><mml:mn>0</mml:mn><mml:mo>,</mml:mo><mml:mn>1</mml:mn><mml:mo stretchy="false">)</mml:mo></mml:math> summarizing patient's toxicity and progression outcomes. Instantaneous cause‐specific hazards of both events, <mml:math id="jats-math-174" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mspace width=".5em"/><mml:mtext>and</mml:mtext><mml:mspace width=".5em"/><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math> were back computed from cumulative incidence values of event assumed at time <mml:math id="jats-math-175" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:mrow></mml:math> at each dose level, using exponentially distributed event times. Competing risks data were then simulated following Beyersmann et al's approach.<xref rid="sim9591-bib-0036" ref-type="bibr"><sup>36</sup></xref> Observations were sampled from an exponential model for the time‐to‐first event <mml:math id="jats-math-176" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>T</mml:mi></mml:mrow></mml:mrow></mml:math> (event‐free survival), with all‐cause hazard <mml:math id="jats-math-177" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mo stretchy="false">(</mml:mo><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub><mml:mo stretchy="false">)</mml:mo></mml:mrow></mml:mrow></mml:math> and the cause of failure determined by a random draw from a Bernoulli distribution with probability <mml:math id="jats-math-178" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mfrac><mml:mrow><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mi>λ</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mfrac></mml:mrow></mml:mrow></mml:math> for toxicity (otherwise disease progression). Last, administrative censoring was applied at time <mml:math id="jats-math-179" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:mrow></mml:math> to mimic the trial observation window. For trials generated under the Clayton model for time‐to‐event data, details are available in the Supporting Web Materials.</p>
              </sec>
              <sec id="sim9591-sec-0012">
                <label>4.4</label>
                <title>Comparative methods</title>
                <p>To evaluate performances of our proposed design, we developed a nonparametric benchmark approach providing an upper bound estimate on selecting the OD under a given scenario, and at a fixed sample size.<xref rid="sim9591-bib-0012" ref-type="bibr"><sup>12</sup></xref>, <xref rid="sim9591-bib-0030" ref-type="bibr"><sup>30</sup></xref>, <xref rid="sim9591-bib-0031" ref-type="bibr"><sup>31</sup></xref> We revised the benchmark approach proposed by Cheung<xref rid="sim9591-bib-0031" ref-type="bibr"><sup>31</sup></xref> for complex designs with a bivariate dose‐finding objective, to account for right‐censored endpoints and competing risks events. These benchmark values for dose selection provide meaningful information on the complexity of scenario in terms of OD identification and provide a reference for the performance of a dose‐finding algorithm with complete potential information, that is, as if outcomes could be observed at all dose levels for all patients. In our setting of a bivariate dose‐finding objective relying on the cumulative incidence of DLT and progression, we computed a benchmark based on two endpoints (toxicity and progression).<xref rid="sim9591-bib-0031" ref-type="bibr"><sup>31</sup></xref> In the presence of informative censoring, cumulative incidences were estimated as described by Gray.<xref rid="sim9591-bib-0037" ref-type="bibr"><sup>37</sup></xref> Non parametric estimators for the benchmark were chosen, similarly to the original benchmark proposal for binary endpoints.<xref rid="sim9591-bib-0030" ref-type="bibr"><sup>30</sup></xref> The OD was estimated from the complete dataset based on the trial objective defined in Equation (<xref rid="sim9591-disp-0002" ref-type="disp-formula">2</xref>). Details of the benchmark approach are provided in Supporting Web Material (Table S1).</p>
                <p>For a comparison purpose in dose selection performances, we also applied the TITE‐BOIN‐ET design<xref rid="sim9591-bib-0022" ref-type="bibr"><sup>22</sup></xref> to the simulation scenarios. With the TITE‐BOIN‐ET design, the method used to guide dose escalation is different from the method used for final estimation. Briefly, for OD estimation at the end of the trial, regression models for each of the toxicity and efficacy outcomes are fitted. For toxicity, an isotonic regression is performed and for efficacy, a model with fractional polynomials with two degrees of freedom is applied. The OD is then determined as the dose that maximizes the efficacy probability among a set satisfying tolerability, that is, dose levels equal or below the MTD (ie, dose with toxicity probability closest to the target toxicity probability <mml:math id="jats-math-180" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mtext>DLT</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>). In our setting, we assumed efficacy when a patient is alive without progression. Thus, the true cumulative incidence of progression at time <mml:math id="jats-math-181" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msup><mml:mrow><mml:mi>t</mml:mi></mml:mrow><mml:mrow><mml:mo>∗</mml:mo></mml:mrow></mml:msup></mml:mrow></mml:mrow></mml:math> are defined as the complementary of the true probability of efficacy. A set‐up for simulations as close as possible to our simulation setting was used for a fair comparison with respect to the maximum number of patients (<mml:math id="jats-math-182" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>N</mml:mi><mml:mo>=</mml:mo><mml:mn>45</mml:mn></mml:mrow></mml:mrow></mml:math>), cohort size (=1), starting dose (<mml:math id="jats-math-183" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>d</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>), assessment windows for toxicity and efficacy (42 days) and accrual rate (one patient per 10 days). For dose assignment during the trial, the target toxicity probability and the target efficacy probability were <mml:math id="jats-math-184" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mtext>DLT</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mo>.</mml:mo><mml:mn>25</mml:mn></mml:mrow></mml:mrow></mml:math> and <mml:math id="jats-math-185" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mtext>EFF</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mo>.</mml:mo><mml:mn>95</mml:mn></mml:mrow></mml:mrow></mml:math>, respectively. To match the Surv‐CRM‐12 dose‐finding objective of minimizing time‐to‐progression, which corresponds to maximizing the efficacy probability in the TITE‐BOIN‐ET setting, we chose to set a target efficacy probability, <mml:math id="jats-math-186" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mtext>EFF</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>, close to 100%. We set the highest acceptable toxicity probability <mml:math id="jats-math-187" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mtext>1 DLT</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mo>.</mml:mo><mml:mn>4</mml:mn><mml:msub><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mtext>DLT</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math> (ie, 60% deviation from the target), the lowest DLT probability that is overly toxic <mml:math id="jats-math-188" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mtext>2 DLT</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>.</mml:mo><mml:mn>4</mml:mn><mml:msub><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mtext>DLT</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>, (ie, 40% deviation from the target), and the highest efficacy probability that is subtherapeutic <mml:math id="jats-math-189" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mtext>1 EFF</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mo>.</mml:mo><mml:mn>6</mml:mn><mml:msub><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mtext>EFF</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math> (ie, 40% deviation from the target). As a result, the optimal values of the lower and upper cutoffs on toxicity and the cutoff on efficacy were estimated to be <mml:math id="jats-math-190" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mo stretchy="false">{</mml:mo><mml:mn>0</mml:mn><mml:mo>.</mml:mo><mml:mn>21</mml:mn><mml:mo>;</mml:mo><mml:mn>0</mml:mn><mml:mo>.</mml:mo><mml:mn>29</mml:mn><mml:mo>;</mml:mo><mml:mn>0</mml:mn><mml:mo>.</mml:mo><mml:mn>80</mml:mn><mml:mo stretchy="false">}</mml:mo></mml:mrow></mml:mrow></mml:math>. We defined safety decisions as close as possible to our setting. Skipping dose(s) was not allowed. Early termination criteria were set as follows: when posterior probability of efficacy was less than 0.05 (ie, <mml:math id="jats-math-191" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mn>1</mml:mn><mml:mo form="prefix">−</mml:mo><mml:msub><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mtext>EFF</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>) was above 0.95, or the posterior probability of toxicity was above 0.25 (ie, <mml:math id="jats-math-192" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mtext>DLT</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>) was above 0.95, the dose was removed. If all doses were removed, the dose‐finding trial was terminated. An early termination rule was applied based on at least 3 patients enrolled in a trial.</p>
                <p>All the simulations were based on 10 000 replicates for the Surv‐CRM‐12 and TITE‐BOIN‐ET designs, and benchmark. For each scenario, we computed the percentage of times that each of the designs selected each dose level as the final OD, percentage of early trial stopping for safety decisions (P<mml:math id="jats-math-193" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mo> </mml:mo><mml:mrow><mml:mtext>stop</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>), the average overdose number (No. OV), defined as the average number of patients treated at a dose above the true OD during the trial,<xref rid="sim9591-bib-0038" ref-type="bibr"><sup>38</sup></xref> the average number of patients that experienced DLT (No. DLT) and disease progression (No. Prog), and the average number of patients treated at the true OD (No. OD).</p>
              </sec>
              <sec id="sim9591-sec-0013">
                <label>4.5</label>
                <title>Results</title>
                <p>Table <xref rid="sim9591-tbl-0001" ref-type="table">1</xref> summarizes the simulation results with a total sample size of 45 patients. As expected, the performance of the methods depended on the scenario. The highest percents of correct selection (PCS) reached by the benchmark, 91% and 97%, were observed in scenarios with more than one OD due to a plateau shape of the dose‐progression relationship (Sc6 and Sc7, respectively). Performances of the proposed Surv‐CRM‐12 design were in line with these findings, as highest PCS, 91% and 93%, were reached for Sc6 and Sc7 respectively. On the other hand, the Surv‐CRM‐12 selected the relatively higher dose levels as the ODs even if the risks of toxicity were increased but acceptable among the dose levels when the risks of disease progression were the same. In scenarios with moderate risk of disease progression and monotone decreasing dose‐progression (Sc1 to Sc5), the Surv‐CRM‐12 correctly selected the OD in more than 60% of cases and outperformed the TITE‐BOIN‐ET method. The Surv‐CRM‐12 seemed robust to different dose‐progression relationships given a fixed risk of toxicity. Indeed, for Sc1 to Sc3, with the same dose‐toxicity relationship and different flat dose‐progression relationships, the Surv‐CRM‐12 provided a satisfactory PCS greater than or equal to 71% and outperformed the benchmark with PCS fluctuating between 52% and 70%. In scenarios with OD at extreme dose levels (Sc5 and Sc12), the Surv‐CRM‐12 picked the OD in 64% and 66% of cases respectively, contrary to 76% and 90% with the benchmark. As expected, the lowest PCS, 27%, was observed in the case of a U‐shape progression scenario (Sc8), while the PCS with the non‐parametric TITE‐BOIN‐ET was 51%, and 80% with the benchmark. Finally, with huge risks of progression, 95% for the first dose level (Sc9, Sc10), the Surv‐CRM‐12 and the TITE‐BOIN‐ET hesitated between the correct dose level and the one above: PCS were 55% and 48% with the Surv‐CRM‐12 for Sc9 and Sc10 respectively, slightly higher than the TITE‐BOIN‐ET (PCS of 43% and 34% respectively), while the PCS with the benchmark were 47% and 69% respectively. To conclude in terms of picking the correct dose, the Surv‐CRM‐12 outperformed the TITE‐BOIN‐ET method over all scenarios except in the case of a U‐shape dose‐progression relationship.</p>
                <table-wrap position="float" id="sim9591-tbl-0001" content-type="TABLE">
                  <label>TABLE 1</label>
                  <caption>
                    <p>Simulation results for Sc1 to Sc6 of the Surv‐CRM‐12 design, TITE‐BOIN‐ET and benchmark; percent of stopped trials for safety (P<mml:math id="jats-math-194" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mo> </mml:mo><mml:mrow><mml:mtext>stop</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>); percent of selection; number of overdose (No. OV); number of observed DLT (No. DLT); number of observed progression (No. Prog) and number of patients treated with the true OD (No. OD) during the trial</p>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col align="left" span="1"/>
                    <col align="left" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/>
                    <col align="left" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/>
                    <col align="left" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/>
                    <col align="left" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/>
                    <col align="left" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/>
                    <col align="left" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/>
                    <col align="left" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/>
                    <col align="left" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/>
                    <col align="left" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/>
                    <col align="left" style="border-right:solid 1px #000000; border-bottom:solid 1px #000000" span="1"/>
                    <thead valign="bottom">
                      <tr>
                        <th align="left" valign="bottom" rowspan="1" colspan="1"/>
                        <th align="left" valign="bottom" rowspan="1" colspan="1"/>
                        <th align="left" colspan="9" style="border-bottom:solid 1px #000000" valign="bottom" rowspan="1">Percent of selection by dose level (%)</th>
                      </tr>
                      <tr style="border-bottom:solid 1px #000000">
                        <th align="left" valign="bottom" rowspan="1" colspan="1">Method</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">P<mml:math id="jats-math-195" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mo> </mml:mo><mml:mrow><mml:mtext>stop</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math> (%)</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">1</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">2</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">3</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">4</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">5</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">No. OV</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">No. DLT</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">No. Prog</th>
                        <th align="left" valign="bottom" rowspan="1" colspan="1">No. OD</th>
                      </tr>
                    </thead>
                    <tbody valign="top">
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Scenario 1</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">True <mml:math id="jats-math-196" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.08</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.14</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>0.25</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.40</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.57</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">True <mml:math id="jats-math-197" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.50</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.48</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>0.45</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.43</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.40</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Surv‐CRM‐12</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">18</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>73</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">9</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">7.0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">11.0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">20.4</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">25.5</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">TITE‐BOIN‐ET</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">15</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">30</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>41</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">9</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">4</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">13.1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">10.4</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">21.5</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">15.3</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Benchmark</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">12</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">34</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>52</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Scenario 2</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">True <mml:math id="jats-math-198" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.08</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.14</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>0.25</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.40</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.57</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">True <mml:math id="jats-math-199" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.30</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.25</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>0.20</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.15</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.10</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Surv‐CRM‐12</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">18</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>71</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">10</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">6.4</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">10.5</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">9.5</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">24.2</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">TITE‐BOIN‐ET</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">14</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">30</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>47</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">8</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">6.3</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">9.1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">10</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">15.2</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Benchmark</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">3</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">28</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>64</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">5</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Scenario 3</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">True <mml:math id="jats-math-200" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.08</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.14</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>0.25</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.40</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.57</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">True <mml:math id="jats-math-201" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.55</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.49</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>0.43</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.36</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.30</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Surv‐CRM‐12</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">17</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>73</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">10</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">7.5</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">11.0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">19.5</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">25.3</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">TITE‐BOIN‐ET</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">12</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">25</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>47</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">12</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">3</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">13.1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">10.7</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">20.3</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">15.8</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Benchmark</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">2</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">25</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>70</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">3</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Scenario 4</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">True <mml:math id="jats-math-202" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.01</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.04</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.08</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>0.20</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.40</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">True <mml:math id="jats-math-203" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.50</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.43</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.37</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>0.30</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.20</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Surv‐CRM‐12</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">4</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>78</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">19</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">7.2</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">8.9</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">13.8</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">26.5</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">TITE‐BOIN‐ET</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">4</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">5</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">16</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>56</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">21</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">14</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">7.9</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">16.6</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">16</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Benchmark</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">9</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>76</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">15</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Scenario 5</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">True <mml:math id="jats-math-204" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.02</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.04</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.08</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.14</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>0.25</bold>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"> True <mml:math id="jats-math-205" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.55</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.48</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.40</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.32</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>0.25</bold>
                        </td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Surv‐CRM‐12</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">35</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>64</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">7.5</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">14.3</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">17.1</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">TITE‐BOIN‐ET</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">5</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">2</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">3</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">11</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">25</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>54</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">6.2</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">19.4</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">26.9</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Benchmark</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">23</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>76</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Scenario 6</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">True <mml:math id="jats-math-206" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.08</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>0.14</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>0.25</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.40</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.57</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">True <mml:math id="jats-math-207" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.50</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>0.45</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>0.45</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.45</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.40</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Surv‐CRM‐12</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>19</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>72</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">9</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">6.9</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">10.9</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">20.6</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">36.5</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">TITE‐BOIN‐ET</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">15</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>33</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>39</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">8</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">4</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">13</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">10.3</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">21.4</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">28</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Benchmark</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">8</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>46</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>45</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Scenario 7</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">True <mml:math id="jats-math-208" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.04</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>0.08</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>0.14</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>0.25</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.40</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1"> True <mml:math id="jats-math-209" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.50</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>0.45</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>0.45</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>0.45</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.40</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Surv‐CRM‐12</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>0</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>26</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>67</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">6</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">3.7</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">9.4</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">20.1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">40.1</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">TITE‐BOIN‐ET</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">8</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>15</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>30</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>30</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">17</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">14.1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">7.5</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">24</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">28</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Benchmark</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">2</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>27</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>36</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>34</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Scenario 8</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">True <mml:math id="jats-math-210" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.04</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.08</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>0.14</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.25</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.40</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">True <mml:math id="jats-math-211" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.50</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.35</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>0.27</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.35</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.50</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Surv‐CRM‐12</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>27</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">67</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">5</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">24.2</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">9.1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">15.1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">16.3</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">TITE‐BOIN‐ET</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">4</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">14</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>50</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">21</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">11</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">21.4</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">6.8</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">19.8</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">14.2</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Benchmark</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">5</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>80</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">15</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Scenario 9</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">True <mml:math id="jats-math-212" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.05</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.15</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>0.25</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.30</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.35</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">True <mml:math id="jats-math-213" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.95</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.65</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>0.45</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.35</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.25</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Surv‐CRM‐12</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">14</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>55</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">26</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">5</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">14.1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">11.0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">21.0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">20.8</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">TITE‐BOIN‐ET</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">18</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>43</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">25</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">13</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">18.1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">9.5</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">23.6</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">13.9</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Benchmark</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">10</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>47</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">31</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">11</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Scenario 10</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">True <mml:math id="jats-math-214" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.05</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.10</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.15</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>0.20</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.25</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">True <mml:math id="jats-math-215" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.95</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.80</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.65</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>0.50</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.55</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Surv‐CRM‐12</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">17</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>48</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">35</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">10.9</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">8.5</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">26.2</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">18.3</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">TITE‐BOIN‐ET</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">4</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">21</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>34</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">40</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">22.3</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">4.7</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">34</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">8.8</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Benchmark</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">11</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>69</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">19</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Scenario 11</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">True <mml:math id="jats-math-216" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.05</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.08</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>0.22</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.35</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.55</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">True <mml:math id="jats-math-217" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.70</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.32</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>0.30</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.28</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.26</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Surv‐CRM‐12</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">4</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>71</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">25</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">12.3</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">10.6</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">13.8</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">25.8</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">TITE‐BOIN‐ET</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">23</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>55</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">18</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">3</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">14.2</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">9.6</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">15.1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">16.9</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Benchmark</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">29</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>61</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">10</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Scenario 12</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">True <mml:math id="jats-math-218" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mn>1</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>0.20</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.40</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.50</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.55</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.62</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">True <mml:math id="jats-math-219" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>F</mml:mi></mml:mrow><mml:mrow><mml:mn>2</mml:mn></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>
</td>
                        <td align="left" valign="top" rowspan="1" colspan="1"/>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>0.50</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.45</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.40</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.38</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0.36</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Surv‐CRM‐12</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">4</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>66</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">29</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">22.1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">13.7</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">21.2</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">22.9</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">TITE‐BOIN‐ET</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">5</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>75</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">18</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">2</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">21.7</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">13.1</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">19.8</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">20.3</td>
                      </tr>
                      <tr>
                        <td align="left" valign="top" rowspan="1" colspan="1">Benchmark</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">
                          <bold>90</bold>
                        </td>
                        <td align="left" valign="top" rowspan="1" colspan="1">10</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">0</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
                        <td align="left" valign="top" rowspan="1" colspan="1">n/a</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <fn id="sim9591-note-0001">
                      <p><italic toggle="yes">Note</italic>: 10 000 simulated trials (Surv‐CRM‐12 design and benchmark) with <mml:math id="jats-math-220" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:mi>N</mml:mi></mml:mrow></mml:mrow></mml:math>=45, <mml:math id="jats-math-221" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mtext>DLT</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mo>.</mml:mo><mml:mn>25</mml:mn></mml:mrow></mml:mrow></mml:math> and <mml:math id="jats-math-222" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>ϵ</mml:mi></mml:mrow><mml:mrow><mml:mi>P</mml:mi></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mo>.</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mrow></mml:math>. 10 000 simulated trials (TITE‐BOIN‐ET) with <mml:math id="jats-math-223" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mtext>DLT</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mo>.</mml:mo><mml:mn>25</mml:mn></mml:mrow></mml:mrow></mml:math>, <mml:math id="jats-math-224" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mtext>EFF</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mo>.</mml:mo><mml:mn>95</mml:mn></mml:mrow></mml:mrow></mml:math>, <mml:math id="jats-math-225" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mtext>1 DLT</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mo>.</mml:mo><mml:mn>4</mml:mn><mml:mo>,</mml:mo><mml:msub><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mtext>DLT</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>, <mml:math id="jats-math-226" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mtext>2 DLT</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>1</mml:mn><mml:mo>.</mml:mo><mml:mn>4</mml:mn><mml:msub><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mtext>DLT</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math> and <mml:math id="jats-math-227" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msub><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mtext>1 EFF</mml:mtext></mml:mrow></mml:msub><mml:mo>=</mml:mo><mml:mn>0</mml:mn><mml:mo>.</mml:mo><mml:mn>6</mml:mn><mml:msub><mml:mrow><mml:mi>π</mml:mi></mml:mrow><mml:mrow><mml:mtext>EFF</mml:mtext></mml:mrow></mml:msub></mml:mrow></mml:mrow></mml:math>. Correct selection results based on ODs are given in boldface.</p>
                    </fn>
                    <fn id="sim9591-note-0002">
                      <p>Abbreviation: n/a, not applicable.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <p>In terms of patient exposure during the trial over the 12 scenarios, the mean number of patients allocated to overdoses (OV) was 10.19 out of a total sample size of 45 patients with the Surv‐CRM‐12 design, below the 14.08 mean value observed with the TITE‐BOIN‐ET. However, fewer patients experienced DLT during the trial using the TITE‐BOIN‐ET: the average number of DLT over all scenarios was 8.73 vs 10.14 with Surv‐CRM‐12. Finally, for 11 out of the 12 scenarios, the average number of patients treated at the true OD was higher with the Surv‐CRM‐12 design and the average OD over all scenarios was 24.95 against 17.88 with the TITE‐BOIN‐ET.</p>
                <p>As shown by Lee and Cheung,<xref rid="sim9591-bib-0032" ref-type="bibr"><sup>32</sup></xref> having a larger prior variance changes the distribution of the prior probability of dose selection from uniform to U‐shaped, leading in higher chances of extreme doses selections. Indeed, with SD equal to <mml:math id="jats-math-228" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msqrt><mml:mrow><mml:mn>1</mml:mn><mml:mo>.</mml:mo><mml:mn>34</mml:mn></mml:mrow></mml:msqrt></mml:mrow></mml:mrow></mml:math>, PCS was higher for Sc5 with OD at level 5, equal to 75%. For Sc12, with OD in dose level 1, PCS was lower with SD equal to <mml:math id="jats-math-229" display="inline" overflow="scroll"><mml:mrow><mml:mrow><mml:msqrt><mml:mrow><mml:mn>1</mml:mn><mml:mo>.</mml:mo><mml:mn>34</mml:mn></mml:mrow></mml:msqrt></mml:mrow></mml:mrow></mml:math>, equal to 59% but the percent of stopped trial for safety decision was much higher (equal to 18% contrary to 4% with the least informative SD) (Table S2 in Supporting Web Materials).</p>
                <p>Expectedly, the performances of all three compared designs improved with increasing sample sizes (Figure S2, Supporting Web Materials). Moreover, the impact of the sample size of the optional first stage was limited (Table S3, Supporting Web Materials), so that this could be left to clinicians' preference.</p>
                <p>Finally, sensitivity simulations showed that the performance of the Surv‐CRM‐12 was mostly preserved in case of correlated events. The PCS was maintained under data generated with correlated times to toxicity and progression, but the POS increased; similar results were observed with the benchmark (Figure S3, Supporting Web Materials).</p>
              </sec>
            </sec>
            <sec id="sim9591-sec-0014">
              <label>5</label>
              <title>DISCUSSION</title>
              <p>In this article, we proposed a novel one‐stage Bayesian adaptive phase I/II design, named the Survival‐CRM‐12, for novel anti‐cancer drugs such as immunotherapies and MTAs, with the purpose to identify the OD defined as the dose with acceptable risk of toxicity and a minimum risk of disease progression. Such a targeted dose, sometimes called the “best” dose<xref rid="sim9591-bib-0017" ref-type="bibr"><sup>17</sup></xref> appeared suitable for such early phase I/II trials, with the aim of maximizing the likelihood of efficacy while only ensuring safety constrains. Our proposed design allows continuous enrollment of patients, and handles competing risks, including the information of time‐to‐event outcomes using survival working models for right‐censored endpoints. It allows the toxicity outcome to be delayed or unobserved due to competing progression within the observation window. Such an issue of late‐onset outcome is common and important in the field of novel anticancer agents. Indeed, it has been reported that 57% of the grades 3‐4 toxicities occur after the treatment cycle 1 in 36 clinical trials of molecularly targeted agents.<xref rid="sim9591-bib-0039" ref-type="bibr"><sup>39</sup></xref> Moreover, disease progression is one of the main cause of premature discontinuation from a Phase I trial (approximately 70% of cases),<xref rid="sim9591-bib-0040" ref-type="bibr"><sup>40</sup></xref> and should be managed other than by ad‐hoc strategies of replacing patients. As demonstrated in the simulation study across a variety of realistic scenarios, and assessed by the benchmark, our proposed method appears an interesting approach in this setting, exhibiting desirable operating characteristics. Indeed, our design performs well in selecting the OD, as well as treating patient at safe doses during the clinical trial.</p>
              <p>Studies have examined the impact of model specification on the performance of the dose‐finding design and have shown the importance of selecting appropriate model parameters via simulation studies.<xref rid="sim9591-bib-0041" ref-type="bibr"><sup>41</sup></xref>, <xref rid="sim9591-bib-0042" ref-type="bibr"><sup>42</sup></xref> Instead of arbitrarily setting initial guesses of the probabilities of DLT and disease progression, and prior variance for model parameters, we proposed a systematic calibration process based on previous literature.<xref rid="sim9591-bib-0032" ref-type="bibr"><sup>32</sup></xref>, <xref rid="sim9591-bib-0033" ref-type="bibr"><sup>33</sup></xref> The calibration method which used jointly the half‐width of the indifference interval both for the toxicity and progression working models, and the least informative prior variance had satisfactory operating characteristics. Jointly calibrating the initial guesses of the probabilities of toxicity and progression at each dose and the prior variance, simplified the calibration process as it reduced the number of parameters to be specified. This approach makes the Bayesian Surv‐CRM‐12 model‐based design more accessible and easier to implement.</p>
              <p>In this phase I/II setting, we chose to model disease progression instead of efficacy, highlighting its competition with the observation of toxicities. Indeed, unlike conventional chemotherapy that works by shrinking the tumor, immunotherapeutic agents often delay cancer progression and prolong survival without achieving rapid tumor shrinkage, and a certain percentage of patients who receive immunotherapy often achieve a long‐term durable response.<xref rid="sim9591-bib-0043" ref-type="bibr"><sup>43</sup></xref> Therefore, for some early phase immunotherapeutic trials, it is preferable to use as efficacy criterion the disease progression, rather than the conventional treatment response. Recently, Zhang et al<xref rid="sim9591-bib-0044" ref-type="bibr"><sup>44</sup></xref> developed a dose finding phase I/II design accounting for the late‐onset competing risk endpoint, relying on piecewise cause‐specific hazard to characterize the competing risk outcomes. However, it treats late‐onset outcomes as missing data while we incorporated them in our model, and requires the definition of a utility function for identifying the OD.</p>
              <p>This study has some limitations. First, we modeled the cause‐specific hazard for progression as a decreasing function of dose. Although a model‐based approach allows the borrowing of information across dose levels, a potential limitation related to this choice of working model is that the Surv‐CRM‐12 tends to select higher doses among safe doses in cases of plateau scenarios for dose‐progression relationship and it does not perform well for U‐shaped dose‐progression relationships. Nonparametric approaches which do not rely on any assumption on the dose‐toxicity and dose‐efficacy curves, may be useful in those situations,<xref rid="sim9591-bib-0045" ref-type="bibr"><sup>45</sup></xref> as the TITE‐BOIN‐ET approach proposed. This approach is part of the model‐assisted designs as its decision rule can be predetermined, but requires specification during the trial planning of several cutoffs by the clinician. A nonparametric approach was also considered with the benchmark method using the complete profiles of outcomes under all dose levels instead of the time‐to‐event outcome under the assigned dose in the Surv‐CRM‐12 or TITE‐BOIN‐ET designs. Nevertheless, the Surv‐CRM‐12 model‐based design outperformed the benchmark in some scenarios, which is not observed with the TITE‐BOIN‐ET model‐assisted design. In sparse settings such as phase I/II clinical, parametric working models may outperform the non‐parametric benchmark in capturing the dose‐response relationships since they allow sharing information across dose levels.<xref rid="sim9591-bib-0038" ref-type="bibr"><sup>38</sup></xref> Second, the “optimal” dose level could have been defined as the dose with both the highest probability of efficacy and the lowest probability of toxicity. This could be the target in particularly frail populations, for example, in neonates and children. However, this assumes equal weighting of toxicity and efficacy, and at the time, the growing accelerated approvals of drugs, notably in oncology, suggests that the target of interest is mostly efficacy.<xref rid="sim9591-bib-0046" ref-type="bibr"><sup>46</sup></xref> Nevertheless, we agree that some consensus regarding the target dose in such trials, should be reached in the future. This would allow a more relevant comparison of all the proposed designs.</p>
              <p>Finally, with the emergence of anti‐cancer molecularly‐targeted agents and immunotherapy agents changing the landscape of dose‐finding in oncology, it is essential to incorporate both late‐onset toxicities and progression information which are often collected as mutually exclusive events into the identification of OD. The proposed phase I/II Surv‐CRM‐12 design achieved the best performance in selecting the OD and allocating patients to the OD when trial discontinuation after disease progression within the observation window is likely to preclude the observation of DLTs in a non‐negligible proportion of patients. It should be considered when designing dose‐finding trials of targeted therapies with prolonged observation windows in advanced cancer patients where treatment discontinuations due to disease progression are likely to occur.</p>
            </sec>
            <sec sec-type="COI-statement" id="sim9591-sec-0016">
              <title>CONFLICT OF INTEREST</title>
              <p>The authors declare no potential conflict of interests.</p>
            </sec>
            <sec sec-type="supplementary-material">
              <title>Supporting information</title>
              <supplementary-material id="sim9591-supitem-0001" position="float" content-type="local-data">
                <caption>
                  <p><bold>Appendix S1</bold> Supporting information</p>
                </caption>
                <media xlink:href="SIM-41-5753-s001.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </sec>
          </body>
          <back>
            <ack id="sim9591-sec-0015">
              <title>ACKNOWLEDGEMENTS</title>
              <p>The authors thank the referees for their constructive comments and insightful suggestions on the manuscript. Shing M. Lee was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant Number UL1TR001873.</p>
            </ack>
            <sec sec-type="data-availability" id="sim9591-sec-1001">
              <title>DATA AVAILABILITY STATEMENT</title>
              <p>Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.</p>
            </sec>
            <ref-list id="sim9591-bibl-0001" content-type="cited-references">
              <title>REFERENCES</title>
              <ref id="sim9591-bib-0001">
                <label>1</label>
                <mixed-citation publication-type="journal" id="sim9591-cit-0001"><string-name><surname>Postel‐Vinay</surname><given-names>S</given-names></string-name>, <string-name><surname>Gomez‐Roca</surname><given-names>C</given-names></string-name>, <string-name><surname>Molife</surname><given-names>LR</given-names></string-name>, et al. <article-title>Phase I trials of molecularly targeted agents: should we pay more attention to late toxicities?</article-title><source>J Clin Oncol</source>. <year>2011</year>;<volume>29</volume>(<issue>13</issue>):<fpage>1728</fpage>‐<lpage>1735</lpage>.<pub-id pub-id-type="pmid">21444876</pub-id></mixed-citation>
              </ref>
              <ref id="sim9591-bib-0002">
                <label>2</label>
                <mixed-citation publication-type="journal" id="sim9591-cit-0002"><string-name><surname>Mathijssen</surname><given-names>RHJ</given-names></string-name>, <string-name><surname>Sparreboom</surname><given-names>A</given-names></string-name>, <string-name><surname>Verweij</surname><given-names>J</given-names></string-name>. <article-title>Determining the optimal dose in the development of anticancer agents</article-title>. <source>Nat Rev Clin Oncol</source>. <year>2014</year>;<volume>11</volume>(<issue>5</issue>):<fpage>272</fpage>‐<lpage>281</lpage>.<pub-id pub-id-type="pmid">24663127</pub-id></mixed-citation>
              </ref>
              <ref id="sim9591-bib-0003">
                <label>3</label>
                <mixed-citation publication-type="journal" id="sim9591-cit-0003"><string-name><surname>Wages</surname><given-names>NA</given-names></string-name>, <string-name><surname>Chiuzan</surname><given-names>C</given-names></string-name>, <string-name><surname>Panageas</surname><given-names>KS</given-names></string-name>. <article-title>Design considerations for early‐phase clinical trials of immune‐oncology agents</article-title>. <source>J Immunother Cancer</source>. <year>2018</year>;<volume>6</volume>(<issue>1</issue>):<fpage>81</fpage>.<pub-id pub-id-type="pmid">30134959</pub-id></mixed-citation>
              </ref>
              <ref id="sim9591-bib-0004">
                <label>4</label>
                <mixed-citation publication-type="journal" id="sim9591-cit-0004"><string-name><surname>Postel‐Vinay</surname><given-names>S</given-names></string-name>, <string-name><surname>Collette</surname><given-names>L</given-names></string-name>, <string-name><surname>Paoletti</surname><given-names>X</given-names></string-name>, et al. <article-title>Towards new methods for the determination of dose limiting toxicities and the assessment of the recommended dose for further studies of molecularly targeted agents–Dose‐Limiting Toxicity and toxicity assessment recommendation group for early trials of targeted therapies, an European organisation for research and treatment of cancer‐led study</article-title>. <source>Eur J Cancer</source>. <year>2014</year>;<volume>50</volume>(<issue>12</issue>):<fpage>2040</fpage>‐<lpage>2049</lpage>.<pub-id pub-id-type="pmid">24880774</pub-id></mixed-citation>
              </ref>
              <ref id="sim9591-bib-0005">
                <label>5</label>
                <mixed-citation publication-type="journal" id="sim9591-cit-0005"><string-name><surname>Cheung</surname><given-names>YK</given-names></string-name>, <string-name><surname>Chappell</surname><given-names>R</given-names></string-name>. <article-title>Sequential designs for Phase I clinical trials with late–Onset toxicities</article-title>. <source>Biometrics</source>. <year>2000</year>;<volume>56</volume>(<issue>4</issue>):<fpage>1177</fpage>‐<lpage>1182</lpage>.<pub-id pub-id-type="pmid">11129476</pub-id></mixed-citation>
              </ref>
              <ref id="sim9591-bib-0006">
                <label>6</label>
                <mixed-citation publication-type="journal" id="sim9591-cit-0006"><string-name><surname>Braun</surname><given-names>TM</given-names></string-name>. <article-title>Generalizing the TITE‐CRM to adapt for early and late‐onset toxicities</article-title>. <source>Stat Med</source>. <year>2006</year>;<volume>25</volume>(<issue>12</issue>):<fpage>2071</fpage>‐<lpage>2083</lpage>.<pub-id pub-id-type="pmid">16217853</pub-id></mixed-citation>
              </ref>
              <ref id="sim9591-bib-0007">
                <label>7</label>
                <mixed-citation publication-type="journal" id="sim9591-cit-0007"><string-name><surname>Yuan</surname><given-names>Y</given-names></string-name>, <string-name><surname>Yin</surname><given-names>G</given-names></string-name>. <article-title>Robust EM continual reassessment method in oncology dose finding</article-title>. <source>J Am Stat Assoc</source>. <year>2011</year>;<volume>106</volume>(<issue>495</issue>):<fpage>818</fpage>‐<lpage>831</lpage>.<pub-id pub-id-type="pmid">22375092</pub-id></mixed-citation>
              </ref>
              <ref id="sim9591-bib-0008">
                <label>8</label>
                <mixed-citation publication-type="journal" id="sim9591-cit-0008"><string-name><surname>Liu</surname><given-names>S</given-names></string-name>, <string-name><surname>Yin</surname><given-names>G</given-names></string-name>, <string-name><surname>Yuan</surname><given-names>Y</given-names></string-name>. <article-title>Bayesian data augmentation dose finding continual reassessment method and delayed toxicity</article-title>. <source>Ann Appl Stat</source>. <year>2013</year>;<volume>7</volume>(<issue>4</issue>):<fpage>1837</fpage>‐<lpage>2457</lpage>.<pub-id pub-id-type="pmid">24707327</pub-id></mixed-citation>
              </ref>
              <ref id="sim9591-bib-0009">
                <label>9</label>
                <mixed-citation publication-type="journal" id="sim9591-cit-0009"><string-name><surname>Yuan</surname><given-names>Y</given-names></string-name>, <string-name><surname>Lin</surname><given-names>R</given-names></string-name>, <string-name><surname>Li</surname><given-names>D</given-names></string-name>, <string-name><surname>Nie</surname><given-names>L</given-names></string-name>, <string-name><surname>Warren</surname><given-names>KE</given-names></string-name>. <article-title>Time‐to‐event Bayesian optimal interval design to accelerate Phase I trials</article-title>. <source>Clin Cancer Res</source>. <year>2018</year>;<volume>24</volume>(<issue>20</issue>):<fpage>4921</fpage>‐<lpage>4930</lpage>.<pub-id pub-id-type="pmid">29769209</pub-id></mixed-citation>
              </ref>
              <ref id="sim9591-bib-0010">
                <label>10</label>
                <mixed-citation publication-type="journal" id="sim9591-cit-0010"><string-name><surname>Lin</surname><given-names>R</given-names></string-name>, <string-name><surname>Yuan</surname><given-names>Y</given-names></string-name>. <article-title>Time‐to‐event model‐assisted designs for dose‐finding trials with delayed toxicity</article-title>. <source>Biostatistics</source>. <year>2020</year>;<volume>21</volume>(<issue>4</issue>):<fpage>807</fpage>‐<lpage>824</lpage>.<pub-id pub-id-type="pmid">30984972</pub-id></mixed-citation>
              </ref>
              <ref id="sim9591-bib-0011">
                <label>11</label>
                <mixed-citation publication-type="journal" id="sim9591-cit-0011"><string-name><surname>Biard</surname><given-names>L</given-names></string-name>, <string-name><surname>Cheng</surname><given-names>B</given-names></string-name>, <string-name><surname>Manji</surname><given-names>GA</given-names></string-name>, <string-name><surname>Lee</surname><given-names>SM</given-names></string-name>. <article-title>A simulation study of methods for handling disease progression in dose‐finding clinical trials</article-title>. <source>J Biopharm Stat</source>. <year>2020</year>;<volume>31</volume>(<issue>2</issue>):<fpage>156</fpage>‐<lpage>167</lpage>.<pub-id pub-id-type="pmid">32931360</pub-id></mixed-citation>
              </ref>
              <ref id="sim9591-bib-0012">
                <label>12</label>
                <mixed-citation publication-type="journal" id="sim9591-cit-0012"><string-name><surname>Andrillon</surname><given-names>A</given-names></string-name>, <string-name><surname>Chevret</surname><given-names>S</given-names></string-name>, <string-name><surname>Lee</surname><given-names>SM</given-names></string-name>, <string-name><surname>Biard</surname><given-names>L</given-names></string-name>. <article-title>Dose‐finding design and benchmark for a right censored endpoint</article-title>. <source>J Biopharm Stat</source>. <year>2020</year>;<volume>30</volume>(<issue>6</issue>):<fpage>948</fpage>‐<lpage>963</lpage>.<pub-id pub-id-type="pmid">33222634</pub-id></mixed-citation>
              </ref>
              <ref id="sim9591-bib-0013">
                <label>13</label>
                <mixed-citation publication-type="journal" id="sim9591-cit-0013"><string-name><surname>Thall</surname><given-names>PF</given-names></string-name>, <string-name><surname>Russell</surname><given-names>KE</given-names></string-name>. <article-title>A strategy for dose‐finding and safety monitoring based on efficacy and adverse outcomes in Phase I/II clinical trials</article-title>. <source>Biometrics</source>. <year>1998</year>;<volume>54</volume>(<issue>1</issue>):<fpage>251</fpage>‐<lpage>264</lpage>.<pub-id pub-id-type="pmid">9544520</pub-id></mixed-citation>
              </ref>
              <ref id="sim9591-bib-0014">
                <label>14</label>
                <mixed-citation publication-type="journal" id="sim9591-cit-0014"><string-name><surname>O'Quigley</surname><given-names>J</given-names></string-name>, <string-name><surname>Hughes</surname><given-names>MD</given-names></string-name>, <string-name><surname>Fenton</surname><given-names>T</given-names></string-name>. <article-title>Dose‐finding designs for HIV studies</article-title>. <source>Biometrics</source>. <year>2001</year>;<volume>57</volume>(<issue>4</issue>):<fpage>1018</fpage>‐<lpage>1029</lpage>.<pub-id pub-id-type="pmid">11764240</pub-id></mixed-citation>
              </ref>
              <ref id="sim9591-bib-0015">
                <label>15</label>
                <mixed-citation publication-type="journal" id="sim9591-cit-0015"><string-name><surname>Braun</surname><given-names>TM</given-names></string-name>. <article-title>The bivariate continual reassessment method. Extending the CRM to Phase I trials of two competing outcomes</article-title>. <source>Control Clin Trials</source>. <year>2002</year>;<volume>23</volume>(<issue>3</issue>):<fpage>240</fpage>‐<lpage>256</lpage>.<pub-id pub-id-type="pmid">12057877</pub-id></mixed-citation>
              </ref>
              <ref id="sim9591-bib-0016">
                <label>16</label>
                <mixed-citation publication-type="journal" id="sim9591-cit-0016"><string-name><surname>Yuan</surname><given-names>Y</given-names></string-name>, <string-name><surname>Yin</surname><given-names>G</given-names></string-name>. <article-title>Bayesian dose finding by jointly modelling toxicity and efficacy as time‐to‐event outcomes</article-title>. <source>J R Stat Soc Ser C Appl Stat</source>. <year>2009</year>;<volume>58</volume>(<issue>5</issue>):<fpage>719</fpage>‐<lpage>736</lpage>.</mixed-citation>
              </ref>
              <ref id="sim9591-bib-0017">
                <label>17</label>
                <mixed-citation publication-type="journal" id="sim9591-cit-0017"><string-name><surname>Wages</surname><given-names>NA</given-names></string-name>, <string-name><surname>Tait</surname><given-names>C</given-names></string-name>. <article-title>Seamless Phase I/II adaptive design for oncology trials of molecularly targeted agents</article-title>. <source>J Biopharm Stat</source>. <year>2015</year>;<volume>25</volume>(<issue>5</issue>):<fpage>903</fpage>‐<lpage>920</lpage>.<pub-id pub-id-type="pmid">24904956</pub-id></mixed-citation>
              </ref>
              <ref id="sim9591-bib-0018">
                <label>18</label>
                <mixed-citation publication-type="journal" id="sim9591-cit-0018"><string-name><surname>Lin</surname><given-names>R</given-names></string-name>, <string-name><surname>Yin</surname><given-names>G</given-names></string-name>. <article-title>STEIN: a simple toxicity and efficacy interval design for seamless Phase I/II clinical trials</article-title>. <source>Stat Med</source>. <year>2017</year>;<volume>36</volume>(<issue>26</issue>):<fpage>4106</fpage>‐<lpage>4120</lpage>.<pub-id pub-id-type="pmid">28786138</pub-id></mixed-citation>
              </ref>
              <ref id="sim9591-bib-0019">
                <label>19</label>
                <mixed-citation publication-type="journal" id="sim9591-cit-0019"><string-name><surname>Takeda</surname><given-names>K</given-names></string-name>, <string-name><surname>Taguri</surname><given-names>M</given-names></string-name>, <string-name><surname>Morita</surname><given-names>S</given-names></string-name>. <article-title>BOIN‐ET: Bayesian optimal interval design for dose finding based on both efficacy and toxicity outcomes</article-title>. <source>Pharm Stat</source>. <year>2018</year>;<volume>17</volume>(<issue>4</issue>):<fpage>383</fpage>‐<lpage>395</lpage>.<pub-id pub-id-type="pmid">29700965</pub-id></mixed-citation>
              </ref>
              <ref id="sim9591-bib-0020">
                <label>20</label>
                <mixed-citation publication-type="journal" id="sim9591-cit-0020"><string-name><surname>Lin</surname><given-names>R</given-names></string-name>, <string-name><surname>Zhou</surname><given-names>Y</given-names></string-name>, <string-name><surname>Yan</surname><given-names>F</given-names></string-name>, <string-name><surname>Li</surname><given-names>D</given-names></string-name>, <string-name><surname>Yuan</surname><given-names>Y</given-names></string-name>. <article-title>BOIN12: Bayesian optimal interval Phase I/II trial design for utility‐based dose finding in immunotherapy and targeted therapies</article-title>. <source>JCO Precis Oncol</source>. <year>2020</year>;<volume>4</volume>:<fpage>1393</fpage>‐<lpage>1402</lpage>.</mixed-citation>
              </ref>
              <ref id="sim9591-bib-0021">
                <label>21</label>
                <mixed-citation publication-type="journal" id="sim9591-cit-0021"><string-name><surname>Jin</surname><given-names>I</given-names></string-name>, <string-name><surname>Liu</surname><given-names>S</given-names></string-name>, <string-name><surname>Thall</surname><given-names>P</given-names></string-name>, <string-name><surname>Yuan</surname><given-names>Y</given-names></string-name>. <article-title>Using data augmentation to facilitate conduct of Phase I‐II clinical trials with delayed outcomes</article-title>. <source>J Am Stat Assoc</source>. <year>2014</year>;<volume>109</volume>(<issue>506</issue>):<fpage>525</fpage>‐<lpage>536</lpage>.<pub-id pub-id-type="pmid">25382884</pub-id></mixed-citation>
              </ref>
              <ref id="sim9591-bib-0022">
                <label>22</label>
                <mixed-citation publication-type="journal" id="sim9591-cit-0022"><string-name><surname>Takeda</surname><given-names>K</given-names></string-name>, <string-name><surname>Morita</surname><given-names>S</given-names></string-name>, <string-name><surname>Taguri</surname><given-names>M</given-names></string-name>. <article-title>TITE‐BOIN‐ET: time‐to‐event Bayesian optimal interval design to accelerate dose‐finding based on both efficacy and toxicity outcomes</article-title>. <source>Pharm Stat</source>. <year>2020</year>;<volume>19</volume>(<issue>3</issue>):<fpage>335</fpage>‐<lpage>349</lpage>.<pub-id pub-id-type="pmid">31829517</pub-id></mixed-citation>
              </ref>
              <ref id="sim9591-bib-0023">
                <label>23</label>
                <mixed-citation publication-type="journal" id="sim9591-cit-0023"><string-name><surname>Biard</surname><given-names>L</given-names></string-name>, <string-name><surname>Lee</surname><given-names>SM</given-names></string-name>, <string-name><surname>Cheng</surname><given-names>B</given-names></string-name>. <article-title>Seamless Phase I/II design for novel anticancer agents with competing disease progression</article-title>. <source>Stat Med</source>. <year>2021</year>;<volume>40</volume>(<issue>21</issue>):<fpage>4568</fpage>‐<lpage>4581</lpage>.<pub-id pub-id-type="pmid">34213022</pub-id></mixed-citation>
              </ref>
              <ref id="sim9591-bib-0024">
                <label>24</label>
                <mixed-citation publication-type="journal" id="sim9591-cit-0024"><string-name><surname>Tsiatis</surname><given-names>A</given-names></string-name>. <article-title>A nonidentifiability aspect of the problem of competing risks</article-title>. <source>Proc Natl Acad Sci</source>. <year>1975</year>;<volume>72</volume>(<issue>1</issue>):<fpage>20</fpage>‐<lpage>22</lpage>.<pub-id pub-id-type="pmid">1054494</pub-id></mixed-citation>
              </ref>
              <ref id="sim9591-bib-0025">
                <label>25</label>
                <mixed-citation publication-type="journal" id="sim9591-cit-0025"><string-name><surname>Andersen</surname><given-names>PK</given-names></string-name>, <string-name><surname>Abildstrom</surname><given-names>SZ</given-names></string-name>, <string-name><surname>Rosthøj</surname><given-names>S</given-names></string-name>. <article-title>Competing risks as a multi‐state model</article-title>. <source>Stat Methods Med Res</source>. <year>2002</year>;<volume>11</volume>(<issue>2</issue>):<fpage>203</fpage>‐<lpage>215</lpage>.<pub-id pub-id-type="pmid">12040697</pub-id></mixed-citation>
              </ref>
              <ref id="sim9591-bib-0026">
                <label>26</label>
                <mixed-citation publication-type="journal" id="sim9591-cit-0026"><string-name><surname>Putter</surname><given-names>H</given-names></string-name>, <string-name><surname>Fiocco</surname><given-names>M</given-names></string-name>, <string-name><surname>Geskus</surname><given-names>RB</given-names></string-name>. <article-title>Tutorial in biostatistics: competing risks and multi‐state models</article-title>. <source>Stat Med</source>. <year>2006</year>;<volume>26</volume>(<issue>11</issue>):<fpage>2389</fpage>‐<lpage>2430</lpage>.</mixed-citation>
              </ref>
              <ref id="sim9591-bib-0027">
                <label>27</label>
                <mixed-citation publication-type="journal" id="sim9591-cit-0027"><string-name><surname>Jeong</surname><given-names>JH</given-names></string-name>, <string-name><surname>Fine</surname><given-names>J</given-names></string-name>. <article-title>Direct parametric inference for the cumulative incidence function</article-title>. <source>J R Stat Soc Ser C Appl Stat</source>. <year>2006</year>;<volume>55</volume>(<issue>2</issue>):<fpage>187</fpage>‐<lpage>200</lpage>.</mixed-citation>
              </ref>
              <ref id="sim9591-bib-0028">
                <label>28</label>
                <mixed-citation publication-type="journal" id="sim9591-cit-0028"><string-name><surname>Benichou</surname><given-names>J</given-names></string-name>, <string-name><surname>Gail</surname><given-names>MH</given-names></string-name>. <article-title>Estimates of absolute cause‐specific risk in cohort studies</article-title>. <source>Biometrics</source>. <year>1990</year>;<volume>46</volume>(<issue>3</issue>):<fpage>813</fpage>‐<lpage>826</lpage>.<pub-id pub-id-type="pmid">2242416</pub-id></mixed-citation>
              </ref>
              <ref id="sim9591-bib-0029">
                <label>29</label>
                <mixed-citation publication-type="journal" id="sim9591-cit-0029"><string-name><surname>Ivanova</surname><given-names>A</given-names></string-name>, <string-name><surname>Wang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Foster</surname><given-names>MC</given-names></string-name>. <article-title>The rapid enrollment design for Phase I clinical trials</article-title>. <source>Stat Med</source>. <year>2016</year>;<volume>35</volume>(<issue>15</issue>):<fpage>2516</fpage>‐<lpage>2124</lpage>.<pub-id pub-id-type="pmid">26833922</pub-id></mixed-citation>
              </ref>
              <ref id="sim9591-bib-0030">
                <label>30</label>
                <mixed-citation publication-type="journal" id="sim9591-cit-0030"><string-name><surname>O'Quigley</surname><given-names>J</given-names></string-name>, <string-name><surname>Paoletti</surname><given-names>X</given-names></string-name>, <string-name><surname>Maccario</surname><given-names>J</given-names></string-name>. <article-title>Non‐parametric optimal design in dose finding studies</article-title>. <source>Biostatistics</source>. <year>2002</year>;<volume>3</volume>(<issue>1</issue>):<fpage>51</fpage>‐<lpage>56</lpage>.<pub-id pub-id-type="pmid">12933623</pub-id></mixed-citation>
              </ref>
              <ref id="sim9591-bib-0031">
                <label>31</label>
                <mixed-citation publication-type="journal" id="sim9591-cit-0031"><string-name><surname>Cheung</surname><given-names>YK</given-names></string-name>. <article-title>Simple benchmark for complex dose finding studies</article-title>. <source>Biometrics</source>. <year>2014</year>;<volume>70</volume>(<issue>2</issue>):<fpage>389</fpage>‐<lpage>397</lpage>.<pub-id pub-id-type="pmid">24571185</pub-id></mixed-citation>
              </ref>
              <ref id="sim9591-bib-0032">
                <label>32</label>
                <mixed-citation publication-type="journal" id="sim9591-cit-0032"><string-name><surname>Lee</surname><given-names>SM</given-names></string-name>, <string-name><surname>Cheung</surname><given-names>YK</given-names></string-name>. <article-title>Calibration of prior variance in the Bayesian continual reassessment method</article-title>. <source>Stat Med</source>. <year>2011</year>;<volume>30</volume>(<issue>17</issue>):<fpage>2081</fpage>‐<lpage>2089</lpage>.<pub-id pub-id-type="pmid">21413054</pub-id></mixed-citation>
              </ref>
              <ref id="sim9591-bib-0033">
                <label>33</label>
                <mixed-citation publication-type="journal" id="sim9591-cit-0033"><string-name><surname>Lee</surname><given-names>SM</given-names></string-name>, <string-name><surname>Cheung</surname><given-names>YK</given-names></string-name>. <article-title>Model calibration in the continual reassessment method</article-title>. <source>Clin Trials</source>. <year>2009</year>;<volume>6</volume>(<issue>3</issue>):<fpage>227</fpage>‐<lpage>238</lpage>.<pub-id pub-id-type="pmid">19528132</pub-id></mixed-citation>
              </ref>
              <ref id="sim9591-bib-0034">
                <label>34</label>
                <mixed-citation publication-type="journal" id="sim9591-cit-0034"><string-name><surname>Wheeler</surname><given-names>GM</given-names></string-name>, <string-name><surname>Mander</surname><given-names>AP</given-names></string-name>, <string-name><surname>Bedding</surname><given-names>A</given-names></string-name>, et al. <article-title>How to design a dose‐finding study using the continual reassessment method</article-title>. <source>BMC Med Res Methodol</source>. <year>2019</year>;<volume>19</volume>(<issue>1</issue>):<fpage>1</fpage>‐<lpage>15</lpage>.<pub-id pub-id-type="pmid">30611213</pub-id></mixed-citation>
              </ref>
              <ref id="sim9591-bib-0035">
                <label>35</label>
                <mixed-citation publication-type="journal" id="sim9591-cit-0035"><string-name><surname>O'Quigley</surname><given-names>J</given-names></string-name>, <string-name><surname>Shen</surname><given-names>LZ</given-names></string-name>. <article-title>Continual reassessment method: a likelihood approach</article-title>. <source>Biometrics</source>. <year>1996</year>;<volume>52</volume>(<issue>2</issue>):<fpage>673</fpage>‐<lpage>684</lpage>.<pub-id pub-id-type="pmid">8672707</pub-id></mixed-citation>
              </ref>
              <ref id="sim9591-bib-0036">
                <label>36</label>
                <mixed-citation publication-type="journal" id="sim9591-cit-0036"><string-name><surname>Beyersmann</surname><given-names>J</given-names></string-name>, <string-name><surname>Latouche</surname><given-names>A</given-names></string-name>, <string-name><surname>Buchholz</surname><given-names>A</given-names></string-name>, <string-name><surname>Schumacher</surname><given-names>M</given-names></string-name>. <article-title>Simulating competing risks data in survival analysis</article-title>. <source>Stat Med</source>. <year>2009</year>;<volume>28</volume>(<issue>6</issue>):<fpage>956</fpage>‐<lpage>971</lpage>.<pub-id pub-id-type="pmid">19125387</pub-id></mixed-citation>
              </ref>
              <ref id="sim9591-bib-0037">
                <label>37</label>
                <mixed-citation publication-type="journal" id="sim9591-cit-0037"><string-name><surname>Gray</surname><given-names>RJ</given-names></string-name>. <article-title>A class of K‐sample tests for comparing the cumulative incidence of a competing risk</article-title>. <source>Ann Stat</source>. <year>1988</year>;<volume>16</volume>(<issue>3</issue>):<fpage>1141</fpage>‐<lpage>1154</lpage>.</mixed-citation>
              </ref>
              <ref id="sim9591-bib-0038">
                <label>38</label>
                <mixed-citation publication-type="book" id="sim9591-cit-0038"><string-name><surname>Cheung</surname><given-names>YK</given-names></string-name>. <source>Dose Finding by the Continual Reassessment Method</source>. <series>Biostatistics Series</series>. <publisher-loc>New York</publisher-loc>: <publisher-name>Chapman &amp; Hall/CRC Press</publisher-name>; <year>2011</year>.</mixed-citation>
              </ref>
              <ref id="sim9591-bib-0039">
                <label>39</label>
                <mixed-citation publication-type="journal" id="sim9591-cit-0039"><string-name><surname>Colin</surname><given-names>P</given-names></string-name>, <string-name><surname>Micallef</surname><given-names>S</given-names></string-name>, <string-name><surname>Delattre</surname><given-names>M</given-names></string-name>, <string-name><surname>Mancini</surname><given-names>P</given-names></string-name>, <string-name><surname>Parent</surname><given-names>E</given-names></string-name>. <article-title>Towards using a full spectrum of early clinical trial data: a retrospective analysis to compare potential longitudinal categorical models for molecular targeted therapies in oncology</article-title>. <source>Stat Med</source>. <year>2015</year>;<volume>34</volume>(<issue>22</issue>):<fpage>2999</fpage>‐<lpage>3016</lpage>.<pub-id pub-id-type="pmid">26059319</pub-id></mixed-citation>
              </ref>
              <ref id="sim9591-bib-0040">
                <label>40</label>
                <mixed-citation publication-type="journal" id="sim9591-cit-0040"><string-name><surname>Olmos</surname><given-names>D</given-names></string-name>, <string-name><surname>A'hern</surname><given-names>R</given-names></string-name>, <string-name><surname>Marsoni</surname><given-names>S</given-names></string-name>, et al. <article-title>Patient selection for oncology Phase I trials: a multi‐institutional study of prognostic factors</article-title>. <source>J Clin Oncol</source>. <year>2012</year>;<volume>30</volume>(<issue>9</issue>):<fpage>996</fpage>‐<lpage>1004</lpage>.<pub-id pub-id-type="pmid">22355064</pub-id></mixed-citation>
              </ref>
              <ref id="sim9591-bib-0041">
                <label>41</label>
                <mixed-citation publication-type="journal" id="sim9591-cit-0041"><string-name><surname>Chevret</surname><given-names>S</given-names></string-name>. <article-title>The continual reassessment method in cancer Phase I clinical trials: a simulation study</article-title>. <source>Stat Med</source>. <year>1993</year>;<volume>12</volume>(<issue>12</issue>):<fpage>1093</fpage>‐<lpage>1108</lpage>.<pub-id pub-id-type="pmid">8210815</pub-id></mixed-citation>
              </ref>
              <ref id="sim9591-bib-0042">
                <label>42</label>
                <mixed-citation publication-type="journal" id="sim9591-cit-0042"><string-name><surname>Paoletti</surname><given-names>X</given-names></string-name>, <string-name><surname>Kramar</surname><given-names>A</given-names></string-name>. <article-title>A comparison of model choices for the continual reassessment method in Phase I cancer trials</article-title>. <source>Stat Med</source>. <year>2009</year>;<volume>28</volume>(<issue>24</issue>):<fpage>3012</fpage>‐<lpage>3028</lpage>.<pub-id pub-id-type="pmid">19672839</pub-id></mixed-citation>
              </ref>
              <ref id="sim9591-bib-0043">
                <label>43</label>
                <mixed-citation publication-type="journal" id="sim9591-cit-0043"><string-name><surname>Topalian</surname><given-names>SL</given-names></string-name>, <string-name><surname>Weiner</surname><given-names>GJ</given-names></string-name>, <string-name><surname>Pardoll</surname><given-names>DM</given-names></string-name>. <article-title>Cancer immunotherapy comes of age</article-title>. <source>J Clin Oncol</source>. <year>2011</year>;<volume>29</volume>(<issue>36</issue>):<fpage>4828</fpage>‐<lpage>4836</lpage>.<pub-id pub-id-type="pmid">22042955</pub-id></mixed-citation>
              </ref>
              <ref id="sim9591-bib-0044">
                <label>44</label>
                <mixed-citation publication-type="journal" id="sim9591-cit-0044"><string-name><surname>Zhang</surname><given-names>Y</given-names></string-name>, <string-name><surname>Cao</surname><given-names>S</given-names></string-name>, <string-name><surname>Zhang</surname><given-names>C</given-names></string-name>, <string-name><surname>Jin</surname><given-names>I</given-names></string-name>, <string-name><surname>Zang</surname><given-names>Y</given-names></string-name>. <article-title>A Bayesian adaptive Phase I/II clinical trial design with late‐onset competing risk outcomes</article-title>. <source>Biometrics</source>. <year>2020</year>;<volume>77</volume>(<issue>3</issue>):<fpage>796</fpage>‐<lpage>808</lpage>.<pub-id pub-id-type="pmid">32735346</pub-id></mixed-citation>
              </ref>
              <ref id="sim9591-bib-0045">
                <label>45</label>
                <mixed-citation publication-type="journal" id="sim9591-cit-0045"><string-name><surname>Cheung</surname><given-names>YK</given-names></string-name>. <article-title>Sequential implementation of stepwise procedures for identifying the maximum tolerated dose</article-title>. <source>J Am Stat Assoc</source>. <year>2007</year>;<volume>102</volume>(<issue>480</issue>):<fpage>1448</fpage>‐<lpage>1461</lpage>.</mixed-citation>
              </ref>
              <ref id="sim9591-bib-0046">
                <label>46</label>
                <mixed-citation publication-type="journal" id="sim9591-cit-0046"><string-name><surname>Sachs</surname><given-names>RE</given-names></string-name>, <string-name><surname>Donohue</surname><given-names>JM</given-names></string-name>, <string-name><surname>Dusetzina</surname><given-names>SB</given-names></string-name>. <article-title>Accelerated approval ‐ taking the FDA's concerns seriously</article-title>. <source>N Engl J Med</source>. <year>2022</year>;<volume>387</volume>(<issue>3</issue>):<fpage>199</fpage>‐<lpage>201</lpage>.<pub-id pub-id-type="pmid">35793197</pub-id></mixed-citation>
              </ref>
            </ref-list>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
